Cancer Research and Treatment

Original Articles

General

Therapeutic Effect of Anti-inflammatory Tripeptide Cream in Hand-Foot Syndrome/Skin Reaction Related to Anticancer Drugs: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial: Yaewon Yang, Jang-Hee Hahn, Min Seo Kim, Minkwan Jo, Yong-Pyo Lee, Hongsik Kim, Hee Kyung Kim, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han; Cancer Res Treat. 2024;56(4):1050-1057. Published online June 5, 2024; DOI: https://doi.org/10.4143/crt.2024.080

Abstract PDF Supplementary Material PubReader ePub: Purpose
Hand-foot syndrome (HFS) and hand-foot skin reaction (HFSR) are relatively common toxicities that interfere with the quality of life (QoL) of patients with cancer. Anti-inflammatory tripeptide cream (ATPC) is a complex formulation of anti-inflammatory tripeptides, the CD99-agonist Binterin and the Wnt-antagonist Winhibin. The present study aimed to assess the therapeutic effects of ATPC in HFS/HFSR associated with anticancer drugs.
Materials and Methods
This was a single-center, randomized, double-blind, placebo-controlled trial. Patients who developed grade 1 HFS/HFSR after systemic anticancer treatments were enrolled, and randomly assigned to receive either ATPC or placebo cream (PC) and followed up at 3-week intervals for up to 9 weeks. Primary endpoint was the development of grade ≥ 2 HFS/HFSR.
Results
Between April 2019 and July 2022, 60 patients (31 in the ATPC and 29 in the PC group) completed the study. The incidence of grade ≥ 2 HFS/HFSR was significantly lower in the ATPC than in the PC group (25.8% vs. 51.7%, p=0.039). The ATPC showed trends towards a better QoL score, assessed by a HFSR and QoL questionnaire at 9 weeks (26.0 vs. 29.9, p=0.574), and a lower frequency of discontinuation, interruption, or dose reduction of anticancer drugs (51.6% vs. 58.6%, p=0.586) than the PC group over 9 weeks, though without statistical significance.
Conclusion
Our results showed that ATPC significantly decreased the development of grade ≥ 2 HFS/HFSR in patients already with HFS/HFSR. Therefore, ATPC may be an effective treatment for HFS/HFSR associated with anticancer drugs.

1,473 View
156 Download

Head and Neck cancer

Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials: Youjin Kim, Bhumsuk Keam, Eun Joo Kang, Jin-Soo Kim, Hye Ryun Kim, Keun-Wook Lee, Jung Hye Kwon, Kyoung Eun Lee, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Moon Young Choi, Ki Hyeong Lee, Sung-Bae Kim, Myung-Ju Ahn; Cancer Res Treat. 2024;56(4):1068-1076. Published online April 15, 2024; DOI: https://doi.org/10.4143/crt.2024.008

Abstract PDF Supplementary Material PubReader ePub: Purpose
In this study, we evaluated 66 patients diagnosed with adenoid cystic carcinoma (ACC) enrolled in two Korean Cancer Study Group trials to investigate the response and progression patterns in recurrent and/or metastatic ACC treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs).
Materials and Methods
We evaluated 66 patients diagnosed with ACC who were enrolled in the Korean Cancer Study Group trials. The tumor measurements, clinical data, treatment outcomes, and progression patterns of therapy were analyzed.
Results
In the 66 patients (53 receiving axitinib and 13 receiving nintedanib), the disease control rate was 61%, and three patients achieved partial response. The median follow-up, median progression-free survival (PFS), overall survival, and 6-month PFS rate were 27.6%, 12.4%, and 18.1% months and 62.1%, respectively. Among 42 patients who experienced progression, 27 (64.3%) showed target lesion progression. Bone metastasis was an independent poor prognostic factor.
Conclusion
Overall, most patients demonstrated stable disease with prolonged PFS; however, prominent target lesion progression occurred in some patients. Thus, PFS may capture VEGFR-TKI efficacy better than the objective response rate.

1,510 View
114 Download

Lung and Thoracic cancer

Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset: Ki Hyeong Lee, Byoung Chul Cho, Myung-Ju Ahn, Yun-Gyoo Lee, Youngjoo Lee, Jong-Seok Lee, Joo-Hang Kim, Young Joo Min, Gyeong-Won Lee, Sung Sook Lee, Kyung-Hee Lee, Yoon Ho Ko, Byoung Yong Shim, Sang-We Kim, Sang Won Shin, Jin-Hyuk Choi, Dong-Wan Kim, Eun Kyung Cho, Keon Uk Park, Jin-Soo Kim, Sang Hoon Chun, Jangyoung Wang, SeokYoung Choi, Jin Hyoung Kang; Cancer Res Treat. 2024;56(1):48-60. Published online June 27, 2023; DOI: https://doi.org/10.4143/crt.2023.453

Abstract PDF Supplementary Material PubReader ePub

Purpose
This subgroup analysis of the Korean subset of patients in the phase 3 LASER301 trial evaluated the efficacy and safety of lazertinib versus gefitinib as first-line therapy for epidermal growth factor receptor mutated (EGFRm) non–small cell lung cancer (NSCLC).
Materials and Methods
Patients with locally advanced or metastatic EGFRm NSCLC were randomized 1:1 to lazertinib (240 mg/day) or gefitinib (250 mg/day). The primary endpoint was investigator-assessed progression-free survival (PFS).
Results
In total, 172 Korean patients were enrolled (lazertinib, n=87; gefitinib, n=85). Baseline characteristics were balanced between the treatment groups. One-third of patients had brain metastases (BM) at baseline. Median PFS was 20.8 months (95% confidence interval [CI], 16.7 to 26.1) for lazertinib and 9.6 months (95% CI, 8.2 to 12.3) for gefitinib (hazard ratio [HR], 0.41; 95% CI, 0.28 to 0.60). This was supported by PFS analysis based on blinded independent central review. Significant PFS benefit with lazertinib was consistently observed across predefined subgroups, including patients with BM (HR, 0.28; 95% CI, 0.15 to 0.53) and those with L858R mutations (HR, 0.36; 95% CI, 0.20 to 0.63). Lazertinib safety data were consistent with its previously reported safety profile. Common adverse events (AEs) in both groups included rash, pruritus, and diarrhoea. Numerically fewer severe AEs and severe treatment–related AEs occurred with lazertinib than gefitinib.
Conclusion
Consistent with results for the overall LASER301 population, this analysis showed significant PFS benefit with lazertinib versus gefitinib with comparable safety in Korean patients with untreated EGFRm NSCLC, supporting lazertinib as a new potential treatment option for this patient population.

Citations

Citations to this article as recorded by

First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis
Jietao Ma, Xiaoxue Pang, Shuling Zhang, Letian Huang, Li Sun, Chengbo Han
Scientific Reports.2024;[Epub] CrossRef

5,732 View
573 Download
1 Crossref

Histologic Changes in Non–Small Cell Lung Cancer under Various Treatments: A Comparison of Histology and Mutation Status in Serial Samples: Chang Gok Woo, Seung-Myoung Son, Ho-Chang Lee, Hye Sook Han, Ki Hyeong Lee, Dohun Kim, Eung-Gook Kim, Ok-Jun Lee; Cancer Res Treat. 2022;54(3):737-743. Published online September 24, 2021; DOI: https://doi.org/10.4143/crt.2021.773

Abstract PDF Supplementary Material PubReader ePub

Purpose
Histologic change is a resistant mechanism in lung cancer. The most common histological change is the switch from adenocarcinoma (AdenoCa) to small cell carcinoma (SCC) against to tyrosine kinase inhibitors (TKI). However, it is not clear whether other treatment modalities are involved in the histologic changes.
Materials and Methods
We investigated histological changes in eight cases, after various treatments, and compared the molecular profiles between primary tumors and changed tumors using exome sequencing where tissue was available.
Results
Three cases of AdenoCa that were changed into SCC retained the initial mutations after TKI and/or surgical treatment. After treatment with TKI and immunotherapy, an EGFR (epidermal growth factor receptor)-mutant AdenoCa changed to squamous cell carcinoma (SqCa). SqCa in a patient treated with surgery was changed into combined AdenoCa and SqCa. These two cases showed the same genetic variations between the two distinct non–small cell carcinomas (NSCC). Three patients experienced two histologic changes, which the changed tumors returned to its original subtype or changed to a combined tumor after treatments. Four cases showed combined histology in the first or second change.
Conclusion
The histology of NSCC can be changed to a single pattern or combined subtypes after various treatment modalities, and the phenotypic changes seem not fixed. Therefore, additional morphologic changes may occur regardless of their genetic status and types of treatments. To refine the new treatment strategy, consecutive repeated biopsies in progressive disease or recurrent tumor are necessary.

Citations

Citations to this article as recorded by

Using ex vivo bioengineered lungs to model pathologies and screening therapeutics: A proof‐of‐concept study
Mohammadali Ahmadipour, Jorge Castilo Prado, Benyamin Hakak‐Zargar, Malik Quasir Mahmood, Ian M. Rogers
Biotechnology and Bioengineering.2024; 121(10): 3020. CrossRef
Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
Shuo Li, Wenyuan Li, Bin Liu, Kostyantyn Krysan, Steven M. Dubinett
Cancer Research Communications.2024; 4(7): 1738. CrossRef
Hepatoid Adenocarcinoma of the Lung: A Review of the Most Updated Literature and a Presentation of Three Cases
Alessandro Bonis, Andrea Dell’Amore, Vincenzo Verzeletti, Luca Melan, Giovanni Zambello, Chiara Nardocci, Giovanni Maria Comacchio, Federica Pezzuto, Fiorella Calabrese, Federico Rea
Journal of Clinical Medicine.2023; 12(4): 1411. CrossRef
Gene‐level dissection of chromosome 3q locus amplification in squamous cell carcinoma of the lung using the nCounter assay
Taesung Jeon, Uk Jeen Oh, Jaeyoung Min, Chungyeul Kim
Thoracic Cancer.2023; 14(26): 2635. CrossRef
Clinical Outcome of Stereotactic Body Radiotherapy in Patients with Early-Stage Lung Cancer with Ground-Glass Opacity Predominant Lesions: A Single Institution Experience
Jeong Yun Jang, Su Ssan Kim, Si Yeol Song, Young Seob Shin, Sei Won Lee, Wonjun Ji, Chang-Min Choi, Eun Kyung Choi
Cancer Research and Treatment.2023; 55(4): 1181. CrossRef
Challenges and Opportunities for Immunoprofiling Using a Spatial High-Plex Technology: The NanoString GeoMx® Digital Spatial Profiler
Sharia Hernandez, Rossana Lazcano, Alejandra Serrano, Steven Powell, Larissa Kostousov, Jay Mehta, Khaja Khan, Wei Lu, Luisa M. Solis
Frontiers in Oncology.2022;[Epub] CrossRef

6,442 View
208 Download
7 Web of Science
6 Crossref

Lung cancer

Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea: Sun Min Lim, Sang-We Kim, Byoung Chul Cho, Jin Hyung Kang, Myung-Ju Ahn, Dong-Wan Kim, Young-Chul Kim, Jin Soo Lee, Jong-Seok Lee, Sung Yong Lee, Keon Uk Park, Ho Jung An, Eun Kyung Cho, Tae Won Jang, Bong-Seog Kim, Joo-Hang Kim, Sung Sook Lee, Im-II Na, Seung Soo Yoo, Ki Hyeong Lee; Cancer Res Treat. 2020;52(4):1112-1119. Published online May 15, 2020; DOI: https://doi.org/10.4143/crt.2020.245

Abstract PDF Supplementary Material PubReader ePub

Purpose
The introduction of immune checkpoint inhibitors represents a major advance in the treatment of lung cancer, allowing sustained recovery in a significant proportion of patients. Nivolumab is a monoclonal anti–programmed death cell protein 1 antibody licensed for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. In this study, we describe the demographic and clinical outcomes of patients with advanced NSCLC treated with nivolumab in the Korean expanded access program.
Materials and Methods
Previously treated patients with advanced non-squamous and squamous NSCLC patients received nivolumab at 3 mg/kg every 2 weeks up to 36 months. Efficacy data including investigator-assessed tumor response, progression data, survival, and safety data were collected.
Results
Two hundred ninety-nine patients were treated across 36 Korean centers. The objective response rate and disease control rate were 18% and 49%, respectively; the median progression-free survival was 2.1 months (95% confidence interval [CI], 1.87 to 3.45), and the overall survival (OS) was 13.2 months (95% CI, 10.6 to 18.9). Patients with smoking history and patients who experienced immune-related adverse events showed a prolonged OS. Cox regression analysis identified smoking history, presence of immune-related adverse events as positive factors associated with OS, while liver metastasis was a negative factor associated with OS. The safety profile was generally comparable to previously reported data.
Conclusion
This real-world analysis supports the use of nivolumab for pretreated NSCLC patients, including those with an older age.

Citations

Citations to this article as recorded by

Advances in reprogramming of energy metabolism in tumor T cells
Liu Xuekai, Song Yan, Chu Jian, Song Yifei, Wu Xinyue, Zhang Wenyuan, Han Shuwen, Yang Xi
Frontiers in Immunology.2024;[Epub] CrossRef
Effectiveness and Safety of PD-1 Inhibitors’ Treatment for Patients with Non-Small-Cell Lung Cancer in China: A Real-World Study
Ning Wan, Yongbang Chen, Liqing Lu, Bing Wang, Liuliu He, Hongyi Liang, Fei Xie, Xiaoshun Jian, Bo Ji, Jianping Zhang, Hammoda Abu-Odah
European Journal of Cancer Care.2024; 2024: 1. CrossRef
Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer
Qiang Chen, Shuo Ying, Jianwen Qin, Li Zhang
Frontiers in Oncology.2024;[Epub] CrossRef
Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index
Ana Ortega-Franco, Clare Hodgson, Haseem Raja, Mathew Carter, Colin Lindsay, Sarah Hughes, Laura Cove-Smith, Paul Taylor, Yvonne Summers, Fiona Blackhall, Raffaele Califano
Targeted Oncology.2022; 17(4): 453. CrossRef
Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis
Handai Xia, Wengang Zhang, Yuqing Zhang, Xiaoling Shang, Yanguo Liu, Xiuwen Wang
Frontiers in Oncology.2022;[Epub] CrossRef
Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
Donghui Wang, Cen Chen, Yanli Gu, Wanjun Lu, Ping Zhan, Hongbing Liu, Tangfeng Lv, Yong Song, Fang Zhang
Frontiers in Oncology.2021;[Epub] CrossRef
Broad-Spectrum Antibiotic Regimen Affects Survival in Patients Receiving Nivolumab for Non-Small Cell Lung Cancer
Min Jung Geum, Chungsoo Kim, Ji Eun Kang, Jae Hee Choi, Jae Song Kim, Eun Sun Son, Sun Min Lim, Sandy Jeong Rhie
Pharmaceuticals.2021; 14(5): 445. CrossRef
Nivolumab

Reactions Weekly.2021; 1855(1): 269. CrossRef
Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis
Zhe Zhao, Xinfeng Wang, Jinghan Qu, Wei Zuo, Yan Tang, Huijuan Zhu, Xiaoguang Chen
Frontiers in Oncology.2021;[Epub] CrossRef

10,449 View
308 Download
15 Web of Science
9 Crossref

The Effect of Disability on the Diagnosis and Treatment of Multiple Myeloma in Korea: A National Cohort Study: Jihyun Kwon, So Young Kim, Kyoung Eun Yeob, Hye Sook Han, Ki Hyeong Lee, Dong Wook Shin, Yeon-Yong Kim, Jong Heon Park, Jong Hyock Park; Cancer Res Treat. 2020;52(1):1-9. Published online April 22, 2019; DOI: https://doi.org/10.4143/crt.2018.702

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to determine whether the diagnosis, treatment approach, and prognosis of multiple myeloma (MM) vary according to the presence and type of disability.
Materials and Methods
Demographic, socioeconomic, and medical data were obtained from the National Disability Database, the Korean Central Cancer Registry, and the Korean National Health Insurance claims database. An age- and sex-matched cohort was established using a 1:3 ratio constituted with 2,776,450 people with disabilities and 8,329,350 people without disabilities. Adult patients diagnosed with MM were subsequently selected from this cohort. Disabilities were categorized as physical, communication, intellectual or psychological, and affecting the major internal organs.
Results
The cohort included 4,090 patients with MM, with a significantly lower rate per 100,000 persons among people with disabilities than among people without disabilities (29.1 vs. 39.4, p < 0.001). People with disabilities were more likely to undergo dialysis treatment at the time of diagnosis (16.3% vs. 10.0%, p < 0.001), but were less likely to undergo autologous stem cell transplantation (37.5% vs. 43.7%, p=0.072). This trend was more evident among patients with intellectual or psychological disabilities. The median overall survival among patients with disabilities was significantly shorter than that among patients without disabilities (36.8 months vs. 51.2 months, p < 0.001).
Conclusion
In Korea, people with disabilities generally have a lower rate of MM diagnosis, receive less intensive treatment, and have a lower survival rate than people without disabilities.

Citations

Citations to this article as recorded by

Case report: IORT as an alternative treatment option for breast cancer patients with difficulty staying still
Fardeen Bhimani, Maureen McEvoy, Yu Chen, Anjuli Gupta, Jessica Pastoriza, Shani Fruchter, Zachary C. Bitan, Wolfgang A. Tomé, Keyur Mehta, Jana Fox, Sheldon Feldman
Frontiers in Oncology.2024;[Epub] CrossRef
The Korea National Disability Registration System
Miso Kim, Wonyoung Jung, So Young Kim, Jong Hyock Park, Dong Wook Shin
Epidemiology and Health.2023; 45: e2023053. CrossRef
Do people with disabilities experience disparities in cancer care? A systematic review
Irene Tosetti, Hannah Kuper, Sina Azadnajafabad
PLOS ONE.2023; 18(12): e0285146. CrossRef
Cancer detection, diagnosis, and treatment for adults with disabilities
Lisa I Iezzoni
The Lancet Oncology.2022; 23(4): e164. CrossRef
Disparities in All-Cause Mortality in Older Patients with Colorectal Cancer According to Disability Status: A Nationwide Analysis
Woo-Ri Lee, Kyu-Tae Han, Mingee Choi, Woorim Kim
Current Oncology.2022; 29(10): 7430. CrossRef
Disparities in prostate cancer diagnosis, treatment, and survival among men with disabilities: Retrospective cohort study in South Korea
Dong Wook Shin, Jinsung Park, Kyoung Eun Yeob, Seok Jung Yoon, Soong-nang Jang, So Young Kim, Jong Heon Park, Jong Hyock Park, Ichiro Kawachi
Disability and Health Journal.2021; 14(4): 101125. CrossRef
Disparities in the Diagnosis, Treatment, and Survival Rate of Cervical Cancer among Women with and without Disabilities
Jin Young Choi, Kyoung Eun Yeob, Seung Hwa Hong, So Young Kim, Eun-Hwan Jeong, Dong Wook Shin, Jong Heon Park, Gil-won Kang, Hak Soon Kim, Jong Hyock Park, Ichiro Kawachi
Cancer Control.2021;[Epub] CrossRef
Disparities in the Diagnosis and Treatment of Gastric Cancer in Relation to Disabilities
Hyoung Woo Kim, Dong Wook Shin, Kyoung Eun Yeob, In Young Cho, So Young Kim, Seon Mee Park, Jong Heon Park, Jong Hyock Park, Ichiro Kawachi
Clinical and Translational Gastroenterology.2020; 11(10): e00242. CrossRef

9,412 View
365 Download
7 Web of Science
8 Crossref

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13: Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Yoon Hee Choi, Hye Ryun Kim, Hoon-Gu Kim, Heui June Ahn, Ha Yeon Lee, Hwan Jung Yun, Jin-Hyoung Kang, Jaeheon Jeong, Moon Young Choi, Sin-Ho Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn; Cancer Res Treat. 2019;51(2):718-726. Published online September 3, 2018; DOI: https://doi.org/10.4143/crt.2018.324

Abstract PDF PubReader ePub

Purpose
The optimal cytotoxic regimens have not been established for patients with non-small cell lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).
Materials and Methods
We conducted a multi-center randomized phase II trial to compare the clinical outcomes between pemetrexed plus cisplatin combination therapy followed by maintenance pemetrexed (PC) and pemetrexed monotherapy (P) after failure of first-line EGFR-TKI. The primary objective was progression-free survival (PFS), and secondary objectives included overall response rate (ORR), overall survival (OS), health-related quality of life (HRQOL), and safety and toxicity profiles.
Results
A total of 96 patientswere randomized, and 91 patientswere treated at 14 centers in Korea. The ORR was 34.8% (16/46) for the PC arm and 17.8% (8/45) for the P arm (p=0.066). With 23.4 months of follow-up, the median PFS was 5.4 months in the PC arm and 6.4 months in the P arm (p=0.114). The median OS was 17.9 months and 15.7 months in PC and P arms, respectively (p=0.787). Adverse events ≥ grade 3 were reported in 12 patients (26.1%) in the PC arm and nine patients (20.0%) in the P arm (p=0.491). The overall time trends of HRQOL were not significantly different between the two arms.
Conclusion
The outcomes of pemetrexed therapy in NSCLC patients with disease progression after firstline EGFR-TKI might not be improved by adding cisplatin.

Citations

Citations to this article as recorded by

Osimertinib with Chemotherapy in EGFR -Mutated NSCLC

New England Journal of Medicine.2024; 390(5): 478. CrossRef
Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors
Balazs Halmos, Pragya Rai, Jae Min, Xiaohan Hu, Diana Chirovsky, Mark Shamoun, Bin Zhao
Frontiers in Oncology.2024;[Epub] CrossRef
Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non–small cell carcinoma
Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
Asia-Pacific Journal of Clinical Oncology.2023; 19(1): 87. CrossRef
Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment
Cheng-Yu Chang, Chung-Yu Chen, Shih-Chieh Chang, Ching-Yi Chen, Yi-Chun Lai, Chun-Fu Chang, Yu-Feng Wei
Frontiers in Oncology.2023;[Epub] CrossRef
Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class
Joseph N. Samuel, Christopher M. Booth, Elizabeth Eisenhauer, Michael Brundage, Scott R. Berry, Bishal Gyawali
JAMA Oncology.2022; 8(6): 879. CrossRef
Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
Ruizhu Sun, Zhansheng Hou, Yankui Zhang, Bo Jiang
Oncology Letters.2022;[Epub] CrossRef
Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid
Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
Lung Cancer.2021; 152: 15. CrossRef
Exploring the role of epidermal growth factor receptor variant III in meningeal tumors
Rashmi Rana, Vaishnavi Rathi, Kirti Chauhan, Kriti Jain, Satnam Singh Chhabra, Rajesh Acharya, Samir Kumar Kalra, Anshul Gupta, Sunila Jain, Nirmal Kumar Ganguly, Dharmendra Kumar Yadav, Timir Tripathi
PLOS ONE.2021; 16(9): e0255133. CrossRef
Risk factors of nephrotoxicity of maintenance pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung
Wang Chun Kwok, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
Lung Cancer.2021; 162: 169. CrossRef
Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
Current Oncology.2021; 28(6): 4894. CrossRef
Real world experience on maintenance chemotherapy with gemcitabine in second line setting for advanced non-small cell lung carcinoma
Wang Chun Kwok, David Chi Leung Lam, Ka Yan Chiang, James Chung Man Ho, Mary Sau Man Ip, Terence Chi Chun Tam
Journal of Chemotherapy.2020; 32(8): 429. CrossRef

9,967 View
348 Download
11 Web of Science
11 Crossref

Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer: Dong-Wan Kim, Hoon-Gu Kim, Joo-Hang Kim, Keunchil Park, Hoon-Kyo Kim, Joung Soon Jang, Bong-Seog Kim, Jin-Hyoung Kang, Kyung Hee Lee, Sang-We Kim, Hun Mo Ryoo, Jin-Soo Kim, Ki Hyeong Lee, Jung Hye Kwon, Jin-Hyuk Choi, Sang Won Shin, Seokyung Hahn, Dae Seog Heo; Cancer Res Treat. 2019;51(1):119-127. Published online March 12, 2018; DOI: https://doi.org/10.4143/crt.2018.019

Abstract PDF Supplementary Material PubReader ePub

Purpose
This randomized phase III study was designed to compare the efficacy and safety of irinote-can plus cisplatin (IP) over etoposide plus cisplatin (EP) in Korean patients with extensive-disease small-cell lung cancer (SCLC).
Materials and Methods
Patients were randomly assigned to receive IP, composed of irinotecan 65 mg/m² intravenously on days 1 and 8+cisplatin 70 mg/m² intravenously on day 1 every 3 weeks, or EP, composed of etoposide 100 mg/m² intravenously on days 1, 2, 3+cisplatin 70 mg/m² intravenously on day 1, every 3 weeks for a maximum of six cycles, until disease progression, or until unacceptable toxicity occurred. The primary endpoint was overall survival.
Results
A total of 362 patients were randomized to IP (n=173) and EP (n=189) arms. There were no significant differences between IP and EP arms for the median overall survival (10.9 months vs. 10.3 months, p=0.120) and the median progression-free survival (6.5 months vs. 5.8 months, p=0.115). However, there was a significant difference in response rate (62.4% vs. 48.2%, p=0.006). The pre-planned subgroup analyses showed that IP was associated with longer overall survival in male (11.3 months vs. 10.1 months, p=0.036), < 65 years old (12.7 months vs. 11.3 months, p=0.024), and Eastern Cooperative Oncology Group performance status 0/1 (12.4 months vs. 10.9 months, p=0.040) patient groups. The severity of treatment-related adverse events such as grade 3/4 anemia, nausea and diarrhea was more frequent in patients treated with IP.
Conclusion
The IP chemotherapy did not significantly improve the survival compared with EP chemotherapy in Korean patients with extensive-disease SCLC.

Citations

Citations to this article as recorded by

Factors associated with posttraumatic stress and anxiety among the parents of babies admitted to neonatal care: a systematic review
Reem Malouf, Sian Harrison, Victoria Pilkington, Charles Opondo, Chris Gale, Alan Stein, Linda S. Franck, Fiona Alderdice
BMC Pregnancy and Childbirth.2024;[Epub] CrossRef
Real world results of locally advanced and metastatic lung cancer patients treated with platinum doublet chemotherapy in first line: Moroccan cohort
Hassan Abdelilah Tafenzi, Farah Choulli, Edwin Kelly Haag, Anass Baladi, Ismail Essaadi, Rhizlane Belbaraka
Translational Oncology.2024; 47: 102015. CrossRef
Clinical Benefits of new Systemic Therapy for Small‐Cell Lung Cancer Over Two Decades: A Cross‐Sectional Study
Yuejing Chen, Honghong Liu, Shaohua Bai, Xuejiao Han, Fei Jin, Bo Cui
The Clinical Respiratory Journal.2024;[Epub] CrossRef
Camptothecin and Its Derivatives from Traditional Chinese Medicine in Combination with Anticancer Therapy Regimens: A Systematic Review and Meta-Analysis
Paul O. Odeniran, Paradise Madlala, Nompumelelo P. Mkhwanazi, Mahmoud E. S. Soliman
Cancers.2024; 16(22): 3802. CrossRef
Efficacy and toxicity profile of first‐line treatment for extensive‐stage small cell lung cancer: A Bayesian network meta‐analysis
Guo Lin, Zhuoran Yao, Kai Kang, Hui Wang, Ren Luo, You Lu
Cancer Medicine.2023; 12(9): 10230. CrossRef
Therapeutic strategy analysis of patients with advanced stage high‐grade neuroendocrine cervical cancer: A real‐world multicenter study
Yuanyuan Zhang, Yi Huang, Suiyu Luo, Lin Li, Hongying Yang, Ziyi Wang, Yongmei Peng, Manni Huang, Jusheng An, Xi Yang, Jing Wang, Chunmei Li, Lingying Wu
International Journal of Gynecology & Obstetrics.2022; 158(3): 722. CrossRef
Systematic evaluation of the efficacy‐effectiveness gap of systemic treatments in extensive disease small cell lung cancer
Christine M. Cramer‐van der Welle, Franz M. N. H. Schramel, Bas J. M. Peters, John W. G. van Putten, Olaf H. Klungel, Harry J. M. Groen, Ewoudt M. W. van de Garde
Pharmacoepidemiology and Drug Safety.2021; 30(4): 445. CrossRef
Treatment Outcomes of 9,994 Patients With Extensive-Disease Small-Cell Lung Cancer From a Retrospective Nationwide Population-Based Cohort in the Korean HIRA Database
Jung Soo Lee, Seoree Kim, Soo-Yoon Sung, Yeo Hyung Kim, Hyun Woo Lee, Ji Hyung Hong, Yoon Ho Ko
Frontiers in Oncology.2021;[Epub] CrossRef
Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
Koichi Ando, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Tsukasa Ohnishi, Hironori Sagara
Current Oncology.2021; 28(2): 1094. CrossRef
Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study
Seo Ree Kim, Ji Hyung Hong, Soo-Yoon Sung, Yeo Hyung Kim, Sang Hoon Chun, Hyun Woo Lee, Jung Soo Lee, Yoon Ho Ko
BMC Cancer.2021;[Epub] CrossRef
Clinical significance of the cachexia index in patients with small cell lung cancer
Se-Il Go, Mi Jung Park, Gyeong-Won Lee
BMC Cancer.2021;[Epub] CrossRef
Sevens Cases of Neuroendocrine Carcinoma of the Nasal and Paranasal Sinuses
Ichiro Sekine, Kan Kishibe, Miki Takahara, Hiroaki Katada, Tatsuya Hayashi, Yasuaki Harabuchi
Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology).2021; 60(2): 169. CrossRef
Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion
Millie Das, Sukhmani K. Padda, Jared Weiss, Taofeek K. Owonikoko
Advances in Therapy.2021; 38(11): 5431. CrossRef
Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
Current Oncology.2021; 28(6): 4894. CrossRef
Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive‐stage disease small cell lung cancer: Results from a randomized controlled trial
Gyeong‐Won Lee, Se‐Il Go, Dong‐Wan Kim, Hoon‐Gu Kim, Joo‐Hang Kim, Ho Jung An, Joung Soon Jang, Bong‐Seog Kim, Seokyung Hahn, Dae Seog Heo
Thoracic Cancer.2020; 11(1): 62. CrossRef
IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer
Mi-Sook Lee, Kyungsoo Jung, Ji-Young Song, Min-Jung Sung, Sung-Bin Ahn, Boram Lee, Doo-Yi Oh, Yoon-La Choi
Molecular Therapy - Oncolytics.2020; 16: 188. CrossRef
Etoposide and cisplatin versus irinotecan and cisplatin as the first‐line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study
Panpan Zhang, Jie Li, Jian Li, Xiaotian Zhang, Jun Zhou, Xicheng Wang, Zhi Peng, Lin Shen, Ming Lu
Cancer.2020; 126(S9): 2086. CrossRef
Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
Hao Chen, Nobuyuki Horita, Kentaro Ito, Hideyuki Nagakura, Yu Hara, Nobuaki Kobayash, Masaki Yamamoto, Makoto Kudo, Takeshi Kaneko
Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef
A Retrospective Cohort Study on Pretreated Neutrophil-to-Lymphocyte Ratio and Prognosis of Small Cell Lung Cancer: Evidence of Effect Modification by Chemotherapy Regimen

Feiwen Liu, Shaozhang Zhou, Liping Tan, Huiqin Jiang, Yucong Huang
Cancer Management and Research.2020; Volume 12: 10341. CrossRef
Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer
Ting Zhou, Zhonghan Zhang, Fan Luo, Yuanyuan Zhao, Xue Hou, Tingting Liu, Kai Wang, Hongyun Zhao, Yan Huang, Li Zhang
JAMA Network Open.2020; 3(10): e2015748. CrossRef
Thérapie ciblée et immunothérapie du cancer bronchique à petites cellules
J.-L. Pujol, C. Goze, C. Pujol, B. Roch
Revue des Maladies Respiratoires Actualités.2019; 11(3): 315. CrossRef
Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis
Fei Xu, Xiaoli Ren, Yuan Chen, Qianxia Li, Ruichao Li, Yu Chen, Shu Xia
BMC Cancer.2018;[Epub] CrossRef
Traitement médical du cancer bronchique à petites cellules : peut-on sortir de l’aire du cisplatine–étoposide ?
Jean-Louis Pujol, Benoît Roch, Camille N. Pujol, Catherine Goze
Bulletin du Cancer.2018;[Epub] CrossRef

12,560 View
516 Download
27 Web of Science
23 Crossref

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors: Jiyoul Yang, Ok-Jun Lee, Seung-Myoung Son, Chang Gok Woo, Yusook Jeong, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han; Cancer Res Treat. 2018;50(3):908-916. Published online September 19, 2017; DOI: https://doi.org/10.4143/crt.2017.378

Abstract PDF PubReader ePub

Purpose
Malignant pleural effusions (MPEs) are often observed in lung cancer, particularly adenocarcinoma. The aim of this study was to investigate epidermal growth factor receptor (EGFR) mutation status in lung adenocarcinoma-associated MPEs (LA-MPEs) and its correlation with efficacy of EGFR tyrosine kinase inhibitor (TKI) therapy.
Materials and Methods
Samples comprised 40 cell blocks of pathologically-confirmed LA-MPEs collected before the start of EGFR TKI therapy. EGFR mutation status was re-evaluated by peptide nucleic acid clamping and the clinical outcomes of EGFR TKI‒treated patients were analyzed retrospectively.
Results
EGFR mutations were detected in 72.5% of LA-MPE cell blocks (29/40). The median progression-free survival for patients with EGFR mutations in LA-MPEs was better than that for patients with wild-type EGFR (7.33 months vs. 2.07 months; hazard ratio, 0.486; 95% confidence interval, 0.206 to 1.144; p=0.032). The objective response rate (ORR) of 26 patients with EGFR mutations in LA-MPEs among the 36 patients with measurable lesions was 80.8%, while the ORR of the 10 patients with wild-type EGFR in LA-MPEs was 10% (p < 0.001). Among the 26 patients with EGFR mutations in LA-MPEs, the ORR of target lesions and LA-MPEs were 88.5% and 61.5%, respectively (p=0.026).
Conclusion
EGFR mutation status in cell blocks of LA-MPEs confirmed by pathologic diagnosis is highly predictive of EGFR TKI efficacy. For patients with EGFR mutations in LA-MPEs, the response to EGFR TKIs seems to be worse for pleural effusions than for solid tumors.

Citations

Citations to this article as recorded by

Cancer‐associated fibroblast‐derived colony‐stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis
Yutang Huang, Xiaoqing Wang, Chunjie Wen, Jingchan Wang, Honghao Zhou, Lanxiang Wu
MedComm.2024;[Epub] CrossRef
Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions
Melissa Wang, Kaitlin Sparrow, Chrystal Chan, Ashley Gillson, Daniel Stollery, Pen Li
Respiratory Medicine.2023; 206: 107093. CrossRef
Malignant pleural effusion diagnosis and therapy
Liangliang Yang, Yue Wang
Open Life Sciences.2023;[Epub] CrossRef
Failure pattern and radiotherapy exploration in malignant pleural effusion non-small cell lung cancer treated with targeted therapy
Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Huiqin Li, Bing Lu
Frontiers in Oncology.2023;[Epub] CrossRef
Impact of thoracic tumor radiotherapy on survival in non‐small‐cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study
Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Haijie Jin, Huiqin Li, Bing Lu
Cancer Medicine.2023; 12(14): 14949. CrossRef
EGFR Mutation is a Prognostic Factor in Lung Cancer Patients with Pleural Dissemination Detected During or After Surgery
Toshiya Fujiwara, Kazuhiko Shien, Motoki Matsuura, Junichi Soh, Hiromasa Yamamoto, Soshi Takao, Yuho Maki, Tsuyoshi Ueno, Ryujiro Sugimoto, Ken Suzawa, Mikio Okazaki, Hiroyuki Tao, Makio Hayama, Masafumi Kataoka, Yoshifumi Sano, Hidetoshi Inokawa, Motohir
Annals of Surgical Oncology.2023; 30(11): 6697. CrossRef
Efficacy of hyperthermic intrathoracic chemotherapy for initially diagnosed lung cancer with symptomatic malignant pleural effusion
Zihui Li, Jie Deng, Fei Yan, Li Liu, Yanling Ma, Jianhai Sun
Scientific Reports.2023;[Epub] CrossRef
Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs
Xinyang Du, Hua Bai, Zhijie Wang, Jianchun Daun, Zheng Liu, Jiachen Xu, Geyun Chang, Yixiang Zhu, Jie Wang
Thoracic Cancer.2022; 13(9): 1289. CrossRef
Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non‐small‐cell lung cancer
Wei Zhang, Wenjuan Han, Bo Yu, Xin Zhao, Gaojun Lu, Wendy Wu, Yi Zhang
Thoracic Cancer.2022; 13(11): 1642. CrossRef
Management of Malignant Pleural Effusion: Where Are We Now?
Julien Guinde, Hervé Dutau, Philippe Astoul
Seminars in Respiratory and Critical Care Medicine.2022; 43(04): 559. CrossRef
Non-Small Cell Lung Cancer with Malignant Pleural Effusion May Require Primary Tumor Radiotherapy in Addition to Drug Treatment
Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Huiqin Li, Bing Lu
Cancer Management and Research.2022; Volume 14: 3347. CrossRef
The impact of smoking status on the progression‐free survival of non‐small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta‐analysis
Xinyi Li, Cong Huang, Xiaohui Xie, Ziyang Wu, Xia Tian, Yibo Wu, Xin Du, Luwen Shi
Journal of Clinical Pharmacy and Therapeutics.2021; 46(2): 256. CrossRef
Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations
Audra J. Schwalk, David E. Ost, Sahara N. Saltijeral, Henriette De La Garza, Roberto F. Casal, Carlos A. Jimenez, Georgie A. Eapen, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Jack Lee, Yasir Elamin, Jianjun Zhang, Jack A. Roth, Stephen S
Chest.2021; 159(3): 1256. CrossRef
Advances in pleural infection and malignancy
Eihab O. Bedawi, Julien Guinde, Najiib M. Rahman, Philippe Astoul
European Respiratory Review.2021; 30(159): 200002. CrossRef
Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions
Maria Alba Sorolla, Anabel Sorolla, Eva Parisi, Antonieta Salud, José M. Porcel
Cancers.2021; 13(11): 2798. CrossRef
Clinical Characteristics and Therapeutic Outcomes of Metastatic Peritoneal Carcinomatosis in Non-Small-Cell Lung Cancer
Tetsuo Tani, Ichiro Nakachi, Shinnosuke Ikemura, Shigenari Nukaga, Keiko Ohgino, Aoi Kuroda, Hideki Terai, Keita Masuzawa, Taro Shinozaki, Kota Ishioka, Yohei Funatsu, Hidefumi Koh, Koichi Fukunaga, Kenzo Soejima
Cancer Management and Research.2021; Volume 13: 7497. CrossRef
LENT Score: Predicting the Survival of Malignant Pleural Effusion – A Prospective Study of Three Years
Sara Raimundo, Ana Isabel Loureiro, Fortunato Vieira, Ana Fernandes
Archivos de Bronconeumología.2020; 56(7): 465. CrossRef
Current applications of molecular testing on body cavity fluids
Daniel Pinto, Fernando Schmitt
Diagnostic Cytopathology.2020; 48(9): 840. CrossRef
Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer
Jianqiang Li, Xingliang Li, Wenxian Wang, Yang Shao, Yiping Zhang, Zhengbo Song
Translational Oncology.2020; 13(8): 100784. CrossRef
Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations
Ning Liu, Min Yu, Tao Yin, Yong Jiang, Xuelian Liao, Jie Tang, Yanying Li, Diyuan Qin, Dan Li, Yongsheng Wang
Signal Transduction and Targeted Therapy.2020;[Epub] CrossRef
LENT Score: Predicting the Survival of Malignant Pleural Effusion – A Prospective Study of Three Years
Sara Raimundo, Ana Isabel Loureiro, Fortunato Vieira, Ana Fernandes
Archivos de Bronconeumología (English Edition).2020; 56(7): 465. CrossRef
Recent Developments in the Management of Malignant Pleural Effusions: a Narrative Review
Clifford E. Coile, Jessie G. Harvey, Michal Senitko
Current Pulmonology Reports.2020; 9(4): 164. CrossRef
Detecting EGFR mutations and ALK/ROS1 rearrangements in non‐small cell lung cancer using malignant pleural effusion samples
Yi Yao, Min Peng, Qinglin Shen, Qinyong Hu, Hongyun Gong, Qingqing Li, Zhongliang Zheng, Bin Xu, Yingge Li, Yi Dong
Thoracic Cancer.2019; 10(2): 193. CrossRef
Making cold malignant pleural effusions hot: driving novel immunotherapies
Pranav Murthy, Chigozirim N. Ekeke, Kira L. Russell, Samuel C. Butler, Yue Wang, James D. Luketich, Adam C. Soloff, Rajeev Dhupar, Michael T. Lotze
OncoImmunology.2019; 8(4): e1554969. CrossRef
Novel insights into the systemic treatment of lung cancer malignant pleural effusion
Claire Tissot, Pierre Gay, Clément Brun, Marios E. Froudarakis
The Clinical Respiratory Journal.2019; 13(3): 131. CrossRef
Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma
Momin T. Siddiqui, Fernando Schmitt, Andrew Churg
Journal of the American Society of Cytopathology.2019; 8(6): 352. CrossRef

10,017 View
279 Download
35 Web of Science
26 Crossref

Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer: Youngjoo Lee, Ki Hyeong Lee, Geon Kook Lee, Soo-Hyun Lee, Kun Young Lim, Jungnam Joo, Yun Jung Go, Jin Soo Lee, Ji-Youn Han; Cancer Res Treat. 2017;49(4):1001-1011. Published online January 13, 2017; DOI: https://doi.org/10.4143/crt.2016.546

Abstract PDF PubReader ePub

Purpose
This phase II study examined whether the addition of simvastatin to afatinib provides a clinical benefit compared with afatinib monotherapy in previously treated patients with nonadenocarcinomatous non-small cell lung cancer (NA-NSCLC).
Materials and Methods
Patientswith advancedNA-NSCLCwho progressed after one ortwo chemotherapy regimens were randomly assigned to a simvastatin (40 mg/day) plus afatinib (40 mg/day) (AS) arm or to an afatinib (A) arm. The primary endpoint was response rate (RR).
Results
Sixty-eight patients were enrolled (36 in the AS arm and 32 in the A arm). The RR was 5.7% (95% confidence interval [CI], 0.7 to 19.2) for AS and 9.4% (95% CI, 2.0 to 25.0) for A (p=0.440). In arms AS and A, the median progression-free survival (PFS) was 1.0 versus 3.6 months (p=0.240) and the overall survival was 10.0 months versus 7.0 months (p=0.930), respectively. Skin rash, stomatitis, and diarrhea were the most common adverse events in both arms. More grade 3 or 4 diarrhea was observed in arm A (18.8% vs. 5.6% in arm AS). In all patients, the median PFS for treatment including afatinib was not correlated with the status of epidermal growth factor receptor (EGFR) mutation (p=0.122), EGFR fluorescence in situ hybridization (p=0.944), or EGFR immunohistochemistry (p=0.976). However, skin rash severity was significantly related to the risk of progression for afatinib (hazard ratio for skin rash grade ≥ 2 vs. grade < 2, 0.44; 95% CI, 0.25 to 0.78; p=0.005).
Conclusion
There were no significant differences in the efficacy between AS and A arms in patients with NA-NSCLC.

Citations

Citations to this article as recorded by

Statins in the Cause and Prevention of Cancer: Confounding by Indication and Mediation by Rhabdomyolysis and Phosphate Toxicity
Ronald B. Brown
Journal of Cardiovascular Development and Disease.2024; 11(9): 296. CrossRef
Unraveling lipid metabolism reprogramming for overcoming drug resistance in melanoma
Ruilong Wang, Qin Yan, Xiao Liu, Jinfeng Wu
Biochemical Pharmacology.2024; 223: 116122. CrossRef
Cardiovascular/anti‐inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta‐analysis of randomized trials
David J. Benjamin, Alyson Haslam, Vinay Prasad
Cancer Medicine.2024;[Epub] CrossRef
The preventative effects of statin on lung cancer development in patients with idiopathic pulmonary fibrosis using the National Health Insurance Service Database in Korea
Yoo Jung Lee, Nayoon Kang, Junghyun Nam, Eung Gu Lee, Jiwon Ryoo, Soon Seog Kwon, Yong Hyun Kim, Hye Seon Kang, Tsai-Ching Hsu
PLOS ONE.2024; 19(3): e0299484. CrossRef
DHCR24 in Tumor Diagnosis and Treatment: A Comprehensive Review
Xin Fu, Zhaosong Wang
Technology in Cancer Research & Treatment.2024;[Epub] CrossRef
β-blockers and statins: exploring the potential off-label applications in breast, colorectal, prostate, and lung cancers
Pedro Gabriel Senger Braga, Janaína da Silva Vieira, Aline Rachel Bezerra Gurgel, Patricia Chakur Brum
Frontiers in Pharmacology.2024;[Epub] CrossRef
The effects of statins in patients with advanced-stage cancers - a systematic review and meta-analysis
Qiang Zhou, Zhihua Jiao, Yuxi Liu, Peter N. Devreotes, Zhenyu Zhang
Frontiers in Oncology.2023;[Epub] CrossRef
Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients
Claes R. Andersson, Jiawei Ye, Kristin Blom, Mårten Fryknäs, Rolf Larsson, Peter Nygren
Anti-Cancer Drugs.2023; 34(1): 92. CrossRef
New insights into the therapeutic potentials of statins in cancer
Chengyu Liu, Hong Chen, Bicheng Hu, Jiajian Shi, Yuchen Chen, Kun Huang
Frontiers in Pharmacology.2023;[Epub] CrossRef
Functional significance of cholesterol metabolism in cancer: from threat to treatment
Mingming Xiao, Jin Xu, Wei Wang, Bo Zhang, Jiang Liu, Jialin Li, Hang Xu, Yingjun Zhao, Xianjun Yu, Si Shi
Experimental & Molecular Medicine.2023; 55(9): 1982. CrossRef
Simvastatin Enhanced Anti-tumor Effects of Bevacizumab against Lung Adenocarcinoma A549 Cells via Abating HIF-1α-Wnt/β-Catenin Signaling Pathway
Xin Tu, Jian Zhang, Wei Yuan, Xia Wu, Zhi Xu, Cuo Qing
Anti-Cancer Agents in Medicinal Chemistry.2023; 23(19): 2083. CrossRef
Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs
Kush K. Patel, Khosrow Kashfi
Biochemical Pharmacology.2022; 196: 114654. CrossRef
Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer
Yoichi Morofuji, Shinsuke Nakagawa, Kenta Ujifuku, Takashi Fujimoto, Kaishi Otsuka, Masami Niwa, Keisuke Tsutsumi
Pharmaceuticals.2022; 15(2): 151. CrossRef
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
Kamal Eltayeb, Silvia La Monica, Marcello Tiseo, Roberta Alfieri, Claudia Fumarola
Cells.2022; 11(3): 413. CrossRef
Effect of Statins on Lung Cancer Molecular Pathways: A Possible Therapeutic Role
Gianmarco Marcianò, Caterina Palleria, Alessandro Casarella, Vincenzo Rania, Emanuele Basile, Luca Catarisano, Cristina Vocca, Luigi Bianco, Corrado Pelaia, Erika Cione, Bruno D’Agostino, Rita Citraro, Giovambattista De Sarro, Luca Gallelli
Pharmaceuticals.2022; 15(5): 589. CrossRef
The effects of epithelial–mesenchymal transitions in COPD induced by cigarette smoke: an update
Xiaoshan Su, Weijing Wu, Zhixing Zhu, Xiaoping Lin, Yiming Zeng
Respiratory Research.2022;[Epub] CrossRef
Scientific Research Directions on the Histopathology and Immunohistochemistry of the Cutaneous Squamous Cell Carcinoma: A Scientometric Study
Iuliu Gabriel Cocuz, Maria Elena Cocuz, Angela Repanovici, Adrian-Horațiu Sabău, Raluca Niculescu, Andreea-Cătălina Tinca, Vlad Vunvulea, Corina Eugenia Budin, Andreea Raluca Szoke, Maria Cătălina Popelea, Raluca Moraru, Titiana Cornelia Cotoi, Ovidiu Sim
Medicina.2022; 58(10): 1449. CrossRef
Lipid metabolism and cancer
Xueli Bian, Rui Liu, Ying Meng, Dongming Xing, Daqian Xu, Zhimin Lu
Journal of Experimental Medicine.2021;[Epub] CrossRef
Simvastatin-romidepsin combination kills bladder cancer cells synergistically
Kazuki Okubo, Kosuke Miyai, Kimi Kato, Takako Asano, Akinori Sato
Translational Oncology.2021; 14(9): 101154. CrossRef
Statins Decrease Programmed Death-Ligand 1 (PD-L1) by Inhibiting AKT and β-Catenin Signaling
Woo-Jin Lim, Mingyu Lee, Yerin Oh, Xue-Quan Fang, Sujin Lee, Chang-Hoon Lim, Jooho Park, Ji-Hong Lim
Cells.2021; 10(9): 2488. CrossRef
ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells
Jillian Hattaway Luttman, Jacob P. Hoj, Kevin H. Lin, Jiaxing Lin, Jing Jin Gu, Clay Rouse, Amanda G. Nichols, Nancie J. MacIver, Kris C. Wood, Ann Marie Pendergast
Cell Reports.2021; 37(4): 109880. CrossRef
Adjuvant statin therapy for oesophageal adenocarcinoma: the STAT-ROC feasibility study
L. Alexandre, A. B. Clark, S. Walton, M. P. Lewis, B. Kumar, E. C. Cheong, H. Warren, S. S. Kadirkamanathan, S. L. Parsons, S. M. Dresner, E. Sims, M. Jones, M. Hammond, M. Flather, Y. K. Loke, A. M. Swart, A. R. Hart
BJS Open.2020; 4(1): 59. CrossRef
Whether statin use improves the survival of patients with glioblastoma?
Yonglin Xie, Qin Lu, Cameron Lenahan, Shuxu Yang, Daoyang Zhou, Xuchen Qi
Medicine.2020; 99(9): e18997. CrossRef
Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
Kazuki Okubo, Makoto Isono, Kosuke Miyai, Takako Asano, Akinori Sato
Cancer Science.2020; 111(1): 112. CrossRef
Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?
Paolo Gelosa, Laura Castiglioni, Marina Camera, Luigi Sironi
Biochemical Pharmacology.2020; 177: 113895. CrossRef
Attenuation of the pro-inflammatory signature of lung cancer-derived mesenchymal stromal cells by statins
Sabine Galland, Patricia Martin, Giulia Fregni, Igor Letovanec, Ivan Stamenkovic
Cancer Letters.2020; 484: 50. CrossRef
Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials
John P. Thomas, Yoon K. Loke, Leo Alexandre
European Journal of Clinical Pharmacology.2020; 76(12): 1639. CrossRef
Statins as Anticancer Agents in the Era of Precision Medicine
Joseph Longo, Jenna E. van Leeuwen, Mohamad Elbaz, Emily Branchard, Linda Z. Penn
Clinical Cancer Research.2020; 26(22): 5791. CrossRef
Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway
Sheng Zhou, Huanji Xu, Qiulin Tang, Hongwei Xia, Feng Bi
Molecular Cancer Therapeutics.2020; 19(1): 135. CrossRef
Repurposed Drugs Trials by Cancer Type
Joseph C. Murray, Benjamin Levy
The Cancer Journal.2019; 25(2): 127. CrossRef
Diverse Stakeholders of Tumor Metabolism: An Appraisal of the Emerging Approach of Multifaceted Metabolic Targeting by 3-Bromopyruvate
Saveg Yadav, Shrish Kumar Pandey, Yugal Goel, Mithlesh Kumar Temre, Sukh Mahendra Singh
Frontiers in Pharmacology.2019;[Epub] CrossRef
Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis
Cheng-Wei Chou, Ching-Heng Lin, Tzu-Hung Hsiao, Chia-Chien Lo, Chih-Ying Hsieh, Cheng-Chung Huang, Yuh-Pyng Sher
Scientific Reports.2019;[Epub] CrossRef
Drug Repurposing of Metabolic Agents in Malignant Glioma
Corinna Seliger, Peter Hau
International Journal of Molecular Sciences.2018; 19(9): 2768. CrossRef
The Effect of Statin Added to Systemic Anticancer Therapy: A Meta-Analysis of Randomized, Controlled Trials
Hyun Joo Jang, Hyeong Su Kim, Jung Han Kim, Jin Lee
Journal of Clinical Medicine.2018; 7(10): 325. CrossRef
Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials
Mohammed A. M. Farooqi, Nikita Malhotra, Som D. Mukherjee, Stephanie Sanger, Sukhbinder K. Dhesy-Thind, Peter Ellis, Darryl P. Leong, Robert M. Lafrenie
PLOS ONE.2018; 13(12): e0209486. CrossRef
Synergistic effect of receptor-interacting protein 140 and simvastatin on the inhibition of proliferation and survival of hepatocellular carcinoma cells
Kun Xia, Panpan Zhang, Jian Hu, Huan Hou, Mingdi Xiong, Junping Xiong, Nianlong Yan
Oncology Letters.2018;[Epub] CrossRef

11,993 View
346 Download
43 Web of Science
36 Crossref

Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results: Yeon Hee Park, Tae Yong Kim, Young-Hyuck Im, Keun-Seok Lee, In Hae Park, Joohyuk Sohn, Soo-Hyeon Lee, Seock-Ah Im, Jee Hyun Kim, Se Hyun Kim, Soo Jung Lee, Su-Jin Koh, Ki Hyeong Lee, Yoon Ji Choi, Eun Kyung Cho, Suee Lee, Seok Yun Kang, Jae Hong Seo, Sung-Bae Kim, Kyung Hae Jung; Cancer Res Treat. 2017;49(2):423-429. Published online August 3, 2016; DOI: https://doi.org/10.4143/crt.2016.191

Abstract PDF PubReader ePub

Purpose
Eribulin mesilate was approved for the treatment of patients with locally advanced or metastatic breast cancer (MBC),who had received at least two chemotherapeutic regimens, including anthracycline and taxane. On the other hand, the efficacy and safety information of eribulin in Korean patients is limited by the lack of clinical trials.
Materials and Methods
In this multicenter, open-label, single-arm, phase IV study, locally advanced or MBC patients were enrolled between June 2013 and April 2014 from 14 centers in Korea. One point four mg/m2 dose of eribulin was administered on days 1 and 8 of every 21 days. The primary endpoint was the frequency and intensity of the treatment emergent adverse event. The secondary endpoint was the disease control rate, which included the rate of complete responses, partial responses, and stable disease.
Results
A total of 101 patients received at least one dose of eribulin and were included in the safety set. The patients received a total of 543 treatment cycles, with a median of three cycles (range, 1 to 31 cycles). The most common adverse event was neutropenia (91.1% of patients, 48.3% of cycles). The frequent non-hematological adverse events included alopecia, decrease in appetite, fatigue/asthenia, and myalgia/arthralgia. The peripheral neuropathy of any grade occurred in 27 patients (26.7%), including grade 3 in two patients. Disease control rate was 52.7% and 51.3% of patients in the full analysis set and per-protocol set, respectively.
Conclusion
This study demonstrated the feasible safety profile and activity of eribulin in Korean patients with MBC.

Citations

Citations to this article as recorded by

Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan
Yu-Ju Lin, Chun-Nan Kuo, Yu Ko
The Breast.2021; 57: 18. CrossRef
Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer
Pei-Hsin Chen, Dah-Cherng Yeh, Heng-Hsin Tung, Chin-Yao Lin
Medicine.2021; 100(47): e27859. CrossRef
Multifarious targets beyond microtubules—role of eribulin in cancer therapy
Priya Seshadri, Barnali Deb, Prashant Kumar
Frontiers in Bioscience-Scholar.2021;[Epub] CrossRef
A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
Min Ho Park, Soo Jung Lee, Woo Chul Noh, Chang Wan Jeon, Seok Won Lee, Gil Soo Son, Byung-In Moon, Jin Sun Lee, Sung Soo Kang, Young Jin Suh, Geumhee Gwak, Tae Hyun Kim, Young Bum Yoo, Hyun-Ah Kim, Min Young Kim, Ju Yeon Kim, Joon Jeong
The Breast.2020; 54: 121. CrossRef
Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan
Kun-Ming Rau, Fu Ou-Yang, Ta-Chung Chao, Yao-Lung Kuo, Tsui-Fen Cheng, Tsu-Yi Chao, Dar-Ren Chen, Yen-Dun Tzeng, Being-Whey Wang, Chun-Yu Liu, Ming-Hung Hu, Yin-Che Lu, Wei-Jen Ou, Chin-Ho Kuo, Chieh-Han Chuang, Jung-Yu Kan, Fang-Ming Chen, Ming-Feng Hou
Breast Cancer Research and Treatment.2018; 170(3): 583. CrossRef
Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy
Bin Zhao, Hong Zhao, Jiaxin Zhao
Critical Reviews in Oncology/Hematology.2018; 128: 110. CrossRef
Angiomodulators in cancer therapy: New perspectives
Lenka Varinska, Peter Kubatka, Jan Mojzis, Anthony Zulli, Katarina Gazdikova, Pavol Zubor, Dietrich Büsselberg, Martin Caprnda, Radka Opatrilova, Iveta Gasparova, Martin Klabusay, Martin Pec, Eitan Fibach, Mariusz Adamek, Peter Kruzliak
Biomedicine & Pharmacotherapy.2017; 89: 578. CrossRef
Eribulin in Advanced Breast Cancer: Safety, Efficacy and New Perspectives
Ornella Garrone, Emanuela Miraglio, Anna Maria Vandone, Paola Vanella, Daniele Lingua, Marco C Merlano
Future Oncology.2017; 13(30): 2759. CrossRef
Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis
Ling Peng, Yun Hong, Xianghua Ye, Peng Shi, Junyan Zhang, Yina Wang, Qiong Zhao
Oncotarget.2017; 8(67): 112076. CrossRef

11,696 View
330 Download
6 Web of Science
9 Crossref

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors: Ji-Youn Han, Ki Hyeong Lee, Sang-We Kim, Young Joo Min, Eunkyung Cho, Youngjoo Lee, Soo-Hyun Lee, Hyae Young Kim, Geon Kook Lee, Byung Ho Nam, Hyesun Han, Jina Jung, Jin Soo Lee; Cancer Res Treat. 2017;49(1):10-19. Published online May 3, 2016; DOI: https://doi.org/10.4143/crt.2016.058

Abstract PDF Supplementary Material PubReader ePub

Purpose
We examined the efficacy of poziotinib, a second-generation epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) in patients with lung adenocarcinoma with activating EGFR mutations, who developed acquired resistance (AR) to EGFR-TKIs.
Materials and Methods
This single-arm phase II study included EGFR-mutant lung adenocarcinoma with AR to erlotinib or gefitinib based on the Jackman criteria. Patients received poziotinib 16 mg orally once daily in a 28-day cycle. The primary endpoint was progression-free survival (PFS). Prestudy tumor biopsies and blood samples were obtained to determine resistance mechanisms.
Results
Thirty-nine patients were treated. Tumor genotyping was determined in 37 patients; 19 EGFR T790M mutations and two PIK3CAmutations were detected in the prestudy tumors, and seven T790M mutations were detected in the plasma assay. Three (8%; 95% confidence interval [CI], 2 to 21) and 17 (44%; 95% CI, 28 to 60) patients had partial response and stable disease, respectively. The median PFS and overall survival were 2.7 months (95% CI, 1.8 to 3.7) and 15.0 months (95% CI, 9.5 to not estimable), respectively. A longer PFS was observed for patients without T790M or PIK3CA mutations in tumor or plasma compared to those with these mutations (5.5 months vs. 1.8 months, p=0.003). The most frequent grade 3 adverse events were rash (59%), mucosal inflammation (26%), and stomatitis (18%). Most patients required one (n=15) or two (n=15) dose reductions.
Conclusion
Low activity of poziotinib was detected in patients with EGFR-mutant non-small cell lung cancer who developed AR to gefitinib or erlotinib, potentially because of severe-toxicityimposed dose limitation.

Citations

Citations to this article as recorded by

Repeat biopsy versus initial biopsy in terms of complication risk factors and clinical outcomes for patients with non-small cell lung cancer: a comparative study of 113 CT-guided needle biopsy of lung lesions
Yangyang Wang, Yongyuan Zhang, Nana Ren, Fangting Li, Lin Lu, Xin Zhao, Zhigang Zhou, Mengyu Gao, Meng Wang
Frontiers in Oncology.2024;[Epub] CrossRef
EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis
Isabella Michelon, Maysa Vilbert, Caio Ernesto do Rego Castro, Carlos Stecca, Maria Inez Dacoregio, Manglio Rizzo, Vladmir Cláudio Cordeiro de Lima, Ludimila Cavalcante
Journal of Personalized Medicine.2024; 14(7): 752. CrossRef
3D bioprinted vascularized lung cancer organoid models with underlying disease capable of more precise drug evaluation
Yoo-mi Choi, Haram Lee, Minjun Ann, Minyeong Song, Jinguen Rheey, Jinah Jang
Biofabrication.2023; 15(3): 034104. CrossRef
Association of Hypokalemia Incidence and Better Treatment Response in NSCLC Patients: A Meta-Analysis and Systematic Review on Anti-EGFR Targeted Therapy Clinical Trials
Jiawei Zhou, Jianling Bai, Yuanping Yue, Xin Chen, Theis Lange, Dongfang You, Yang Zhao
Frontiers in Oncology.2022;[Epub] CrossRef
Anlotinib plus chemotherapy for T790M‐negative EGFR‐mutant non‐sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial
Juan Li, Yuke Tian, Min Zheng, Jun Ge, Jiliang Zhang, Dejun Kong, Mei Chen, Ping Yu
Thoracic Cancer.2022; 13(24): 3496. CrossRef
Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers
Vidhi Malik, Vipul Kumar, Sunil C. Kaul, Renu Wadhwa, Durai Sundar
Biomolecules.2021; 11(2): 160. CrossRef
Validation of a multicellular tumor microenvironment system for modeling patient tumor biology and drug response
Devin G. Roller, Stephen A. Hoang, Kristopher D. Rawls, Katherine A. Owen, Michael B. Simmers, Robert A. Figler, Julia D. Wulfkuhle, Emanuel F. Petricoin, Brian R. Wamhoff, Daniel Gioeli
Scientific Reports.2021;[Epub] CrossRef
Epidermal growth factor receptor inhibitor-induced diarrhea: clinical incidence, toxicological mechanism, and management
Gabriel Tao, Pavan Kumar Chityala
Toxicology Research.2021; 10(3): 476. CrossRef
Geriatric Nutritional Risk Index as a Prognostic Factor for Mortality in Elderly Patients with Moderate to Severe Traumatic Brain Injuries
Wei-Ti Su, Ching-Hua Tsai, Chun-Ying Huang, Sheng-En Chou, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh
Risk Management and Healthcare Policy.2021; Volume 14: 2465. CrossRef
Geriatric nutritional risk index in screening malnutrition among young adult and elderly trauma patients
Yueh-Wei Liu, Ching-Hua Tsai, Sheng-En Chou, Wei-Ti Su, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh
Formosan Journal of Surgery.2021; 54(5): 183. CrossRef
In silico studies on p21-activated kinase 4 inhibitors: comprehensive application of 3D-QSAR analysis, molecular docking, molecular dynamics simulations, and MM-GBSA calculation
Yinli Gao, Hanxun Wang, Jian Wang, Maosheng Cheng
Journal of Biomolecular Structure and Dynamics.2020; 38(14): 4119. CrossRef
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
Iosune Baraibar, Laura Mezquita, Ignacio Gil-Bazo, David Planchard
Critical Reviews in Oncology/Hematology.2020; 148: 102906. CrossRef
Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
Afshin Derakhshani, Zohreh Rezaei, Hossein Safarpour, Morteza Sabri, Atefeh Mir, Mohammad Amin Sanati, Fatemeh Vahidian, Ali Gholamiyan Moghadam, Ali Aghadoukht, Khalil Hajiasgharzadeh, Behzad Baradaran
Journal of Cellular Physiology.2020; 235(4): 3142. CrossRef
Toward a More Precise Future for Oncology
Yonina R. Murciano-Goroff, Barry S. Taylor, David M. Hyman, Alison M. Schram
Cancer Cell.2020; 37(4): 431. CrossRef
Nanocarrier centered therapeutic approaches: Recent developments with insight towards the future in the management of lung cancer
Jigar D. Vanza, Rashmin B. Patel, Mrunali R. Patel
Journal of Drug Delivery Science and Technology.2020; 60: 102070. CrossRef
Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
Yongchao Zhang, Zhuo-Xun Wu, Yuqi Yang, Jing-Quan Wang, Jun Li, Zoey Sun, Qiu-Xu Teng, Charles R. Ashby, Dong-Hua Yang
Cancers.2020; 12(11): 3249. CrossRef
Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib
Nishan Tchekmedyian, Bill Paxton, Francois Lebel, Lena Keossayan, John V. Heymach
JTO Clinical and Research Reports.2020; 1(4): 100081. CrossRef
Geriatric Nutritional Risk Index as a Screening Tool to Identify Patients with Malnutrition at a High Risk of In-Hospital Mortality among Elderly Patients with Femoral Fractures—A Retrospective Study in a Level I Trauma Center
Wei-Ti Su, Shao-Chun Wu, Chun-Ying Huang, Sheng-En Chou, Ching-Hua Tsai, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh
International Journal of Environmental Research and Public Health.2020; 17(23): 8920. CrossRef
Geriatric Nutritional Risk Index as a Tool to Evaluate Impact of Malnutrition Risk on Mortality in Adult Patients with Polytrauma
Cheng-Hsi Yeh, Shao-Chun Wu, Sheng-En Chou, Wei-Ti Su, Ching-Hua Tsai, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh
International Journal of Environmental Research and Public Health.2020; 17(24): 9233. CrossRef
Association between Geriatric Nutritional Risk Index and Mortality in Older Trauma Patients in the Intensive Care Unit
Hang-Tsung Liu, Shao-Chun Wu, Ching-Hua Tsai, Chi Li, Sheng-En Chou, Wei-Ti Su, Shiun-Yuan Hsu, Ching-Hua Hsieh
Nutrients.2020; 12(12): 3861. CrossRef
Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
Rashmi R. Shah, Devron R. Shah
Drug Safety.2019; 42(2): 181. CrossRef
Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
Wei Jiang, Meiju Ji
Seminars in Cancer Biology.2019; 59: 3. CrossRef
Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Non–Small-Cell Lung Cancer
Juliane Martin, Annika Lehmann, Frederick Klauschen, Michael Hummel, Dido Lenze, Christian Grohé, Antje Tessmer, Joachim Gottschalk, Berndt Schmidt, Hans-Wilhelm Pau, Christian Witt, Stefan Moegling, Robert Kromminga, Korinna Jöhrens
Clinical Lung Cancer.2019; 20(5): 350. CrossRef
Metastasiertes Lungenkarzinom – therapierbare molekulare Alterationen
W. M. Brückl, J. H. Ficker
Der Pneumologe.2019; 16(6): 343. CrossRef
Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib
Juyin Yang, Jian Yang, Shao Ban, Xinmin Li, Xingde Chen, Jihua Yang, Jun Qian
Journal of Thoracic Oncology.2019; 14(9): e198. CrossRef
Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective
Shui-Ming Bao, Qing-Hui Hu, Wen-Ting Yang, Yao Wang, Yin-Ping Tong, Wen-Dai Bao
Anti-Cancer Agents in Medicinal Chemistry.2019; 19(8): 984. CrossRef
Maximum allele frequency observed in plasma: A potential indicator of liquid biopsy sensitivity
Yong Tang, Xianling Liu, Zhu'an Ou, Zhe He, Qihang Zhu, Ye Wang, Mei Yang, Junyi Ye, Han Han‑Zhang, Guibin Qiao
Oncology Letters.2019;[Epub] CrossRef
TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi, Rumi Fujioka, Yumi Hakozaki, Mikiko Shibuya, Naomi Abe, Toshiharu Komori, Tomonori Haruma, Miki Terasaka, Ryoto Fujita, Akihiro Hashimoto, Kaoru Funabashi, Hiroyuki Yasuda, Kazutaka Miyadera, Koichi Goto, D
Molecular Cancer Research.2019; 17(11): 2233. CrossRef
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor
Chengying Xie, Xiaozhe Wan, Haitian Quan, Mingyue Zheng, Li Fu, Yun Li, Liguang Lou
Cancer Science.2018; 109(4): 1207. CrossRef
Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
Jacqulyne P. Robichaux, Yasir Y. Elamin, Zhi Tan, Brett W. Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada-Bernal, Anh T. Le, Anna Truini, Monique B. Nilsson, Huiying Sun, Emily Roarty, Sarah B. Goldberg, Julie R.
Nature Medicine.2018; 24(5): 638. CrossRef
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma
In-Jae Oh, Jae Young Hur, Cheol-Kyu Park, Young-Chul Kim, Seung Joon Kim, Min Ki Lee, Hee Joung Kim, Kye Young Lee, Jae Cheol Lee, Chang-Min Choi
Clinical Lung Cancer.2018; 19(5): e775. CrossRef
Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors
Yanmei Peng, Qiang Li, Jingyi Zhang, Wen Shen, Xu Zhang, Chenyao Sun, Huijuan Cui
BioScience Trends.2018; 12(6): 537. CrossRef
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa
Clinical Cancer Research.2018; 24(24): 6548. CrossRef
EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs
Zhiyong Liang, Ying Cheng, Yuan Chen, Yanping Hu, Wei-Ping Liu, You Lu, Jie Wang, Ye Wang, Gang Wu, Jian-Ming Ying, He-Long Zhang, Xu-Chao Zhang, Yi-Long Wu
Cancer Letters.2017; 403: 186. CrossRef
Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer
Xuefei Li, Caicun Zhou
Oncotarget.2017; 8(59): 100801. CrossRef

14,418 View
563 Download
37 Web of Science
35 Crossref

A Pilot Study Evaluating Steroid-Induced Diabetes after Antiemetic Dexamethasone Therapy in Chemotherapy-Treated Cancer Patients: Yusook Jeong, Hye Sook Han, Hyo Duk Lee, Jiyoul Yang, Jiwon Jeong, Moon Ki Choi, Jihyun Kwon, Hyun-Jung Jeon, Tae-Keun Oh, Ki Hyeong Lee, Seung Taik Kim; Cancer Res Treat. 2016;48(4):1429-1437. Published online February 29, 2016; DOI: https://doi.org/10.4143/crt.2015.464

Abstract PDF PubReader ePub

Purpose
Dexamethasone is a mainstay antiemetic regimen for the prevention of chemotherapy-induced nausea and vomiting. The aim of this pilot study was to assess the incidence of and factors associated with steroid-induced diabetes in cancer patients receiving chemotherapy with dexamethasone as an antiemetic.
Materials and Methods
Non-diabetic patients with newly diagnosed gastrointestinal cancer who received at least three cycles of highly or moderately emetogenic chemotherapy with dexamethasone as an antiemetic were enrolled. Fasting plasma glucose levels, 2-hour postprandial glucose levels, and hemoglobin A1C tests for the diagnosis of diabetes were performed before chemotherapy and at 3 and 6 months after the start of chemotherapy. The homeostasis model assessment of insulin resistance (HOMA-IR) was used as an index for measurement of insulin resistance, defined as a HOMA-IR ≥ 2.5.
Results
Between January 2012 and November 2013, 101 patients with no history of diabetes underwent laboratory tests for assessment of eligibility; 77 of these patients were included in the analysis. Forty-five patients (58.4%) were insulin resistant and 17 (22.1%) developed steroid-induced diabetes at 3 or 6 months after the first chemotherapy, which included dexamethasone as an antiemetic. Multivariate analysis showed significant association of the incidence of steroid-induced diabetes with the cumulative dose of dexamethasone (p=0.049).
Conclusion
We suggest that development of steroid-induced diabetes after antiemetic dexamethasone therapy occurs in approximately 20% of non-diabetic cancer patients; this is particularly significant for patients receiving high doses of dexamethasone.

Citations

Citations to this article as recorded by

Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)
Hiroko Minatogawa, Naoki Izawa, Kazuhiro Shimomura, Hitoshi Arioka, Hirotoshi Iihara, Mitsuhiro Sugawara, Hajime Morita, Ayako Mochizuki, Shuichi Nawata, Keisuke Mishima, Ayako Tsuboya, Tempei Miyaji, Kazunori Honda, Ayako Yokomizo, Naoya Hashimoto, Takes
British Journal of Cancer.2024; 130(2): 224. CrossRef
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-
Daiki Tsuji, Shigeru Nakagaki, Itsuki Yonezawa, Kenichi Suzuki, Takashi Yokokawa, Yohei Kawasaki, Takumi Yamaguchi, Takashi Kawaguchi, Masahiro Hatori, Takuma Matsumoto, Yukio Sakata, Keisuke Yamamoto, Tomoyasu Nishimura, Yuki Kogure, Toshinobu Hayashi, M
Investigational New Drugs.2024; 42(1): 44. CrossRef
Change in abdominal obesity after colon cancer surgery – effects of left-sided and right-sided colonic resection
Younes Kays Mohammed Ali, Troels Gammeltoft Dolin, Janus Damm Nybing, Jakob Lykke, Frederik Hvid Linden, Erik Høgh-Schmidt, Thorkild I. A. Sørensen, Jesper Frank Christensen, Yousef J. W. Nielsen, Jim Stenfatt Larsen, Sten Madsbad, Julia Sidenius Johansen
International Journal of Obesity.2024; 48(4): 533. CrossRef
Dexamethasone-Free Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy: A Double-Blind, Phase III Randomized Controlled Trial (CINV POD study)
Venkatraman Radhakrishnan, Kritthivasan Venkatakrishnan, Jayachandran Perumal Kalaiyarasi, Gangothri Selvarajan, Nizamudin Mahaboobasha, Paulson Vijaykumar Victor, Malarvizhi Anbazhagan, Deyva Manohari Sivanandam, Swaminathan Rajaraman
JCO Global Oncology.2024;[Epub] CrossRef
Glucocorticoid-Induced Hyperglycemia: A Neglected Problem
Jung-Hwan Cho, Sunghwan Suh
Endocrinology and Metabolism.2024; 39(2): 222. CrossRef
The impact of surgery and oncological treatment on risk of type 2 diabetes onset in patients with colorectal cancer: nationwide cohort study in Denmark
Caroline Krag, Maria Saur Svane, Sten Madsbad, Susanne Boel Graversen, Jesper Frank Christensen, Thorkild IA Sørensen, Louise Lang Lehrskov, Tinne Laurberg
eLife.2024;[Epub] CrossRef
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Jap
Ayako Yokomizo, Kazuhisa Nakashima, Arisa Iba, Kenji Okita, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K. Imamura, Ayako Okuyama, Keiko Ozawa, Yong-Il Kim, Hidenori Sasaki, Eriko Satomi, Masayuki Takeda, Ryuhei Tanaka, Takako Eguchi N
International Journal of Clinical Oncology.2024; 29(11): 1632. CrossRef
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clin
Kazuhisa Nakashima, Ayako Yokomizo, Michiyasu Murakami, Kenji Okita, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K. Imamura, Ayako Okuyama, Keiko Ozawa, Yong-il Kim, Hidenori Sasaki, Eriko Satomi, Masayuki Takeda, Ryuhei Tanaka, Takako
International Journal of Clinical Oncology.2024; 29(12): 1785. CrossRef
Corticosteroid therapy in older adults with cancer: Expert recommendations from a task force of the International Society of Geriatric Oncology
Rupert Bartsch, Daniel Aletaha, Thorsten Fuereder, Matti Aapro, Francois R. Jornayvaz, Pierre-Olivier Lang, Denis Migliorini, Chantal Csajka, Marie-Bernadette Aretin, Vérène Dougoud-Chauvin
Journal of Geriatric Oncology.2024; : 102077. CrossRef
Diabetes and cancer: Optimising glycaemic control
Nalinie Joharatnam‐Hogan, Daniel L. Morganstein
Journal of Human Nutrition and Dietetics.2023; 36(2): 504. CrossRef
Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)
Luigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, Luigi Cavanna, Olga Martelli, Simona Carnio, Elena Collovà, Federica Bertolini, Fausto Petrelli, Alessandra Cassano, Rita Chiari, Francesca Zanelli, Salvatore Pisconti, Isabella Vittimberga, Antonietta
Scientific Reports.2023;[Epub] CrossRef
Diabetes and cancer co-management: patient-reported challenges, needs, and priorities
Laura C. Pinheiro, Jacklyn Cho, Julia Rothman, Caroline Zeng, Micayla Wilson, Lisa M. Kern, Rulla M. Tamimi, Monika M. Safford
Supportive Care in Cancer.2023;[Epub] CrossRef
Link between Blood Cell-Associated Inflammatory Indices and Chemotherapy-Induced Hyperglycemia in Women Affected with Breast Cancer: Clinical Studies
Krishna Prasad, Suresh Rao, Sanath Kumar Hegde, Thomas George, Rhea Katherine D'souza, Sucharitha Suresh, Manjeshwar Shrinath Baliga
South Asian Journal of Cancer.2023; 12(02): 118. CrossRef
Hyperglycemia and Glycemic Variability Associated with Glucocorticoids in Women without Pre-Existing Diabetes Undergoing Neoadjuvant or Adjuvant Taxane Chemotherapy for Early-Stage Breast Cancer
Dana Mahin, Sayeh Moazami Lavasani, Leon Cristobal, Niki Tank Patel, Mina Sedrak, Daphne Stewart, James Waisman, Yuan Yuan, Wai Yu, Raynald Samoa, Nora Ruel, Susan E. Yost, Hayley Lee, Sung Hee Kil, Joanne E. Mortimer
Journal of Clinical Medicine.2023; 12(5): 1906. CrossRef
Dexamethasone-free antiemetic strategy for highly emetogenic chemotherapy: safety and efficacy-pilot study
Vinod Sharma, Akash Kumar, Annie Baa, Sudhir Kirar, Atul Sharma, Sameer Bakhshi, Ajay Gogia, Prabhat Singh Malik, Sameer Rastogi, Atul Batra, Deepam Pushpam, Babita Kataria, Hari Sagiraju, Aparna Sharma, Vishwajeet Singh
BMJ Supportive & Palliative Care.2023; 13(e3): e867. CrossRef
Identifying patients with diabetes in a day‐case systemic anti‐cancer therapy population: the Belfast Regional Oncology Centre experience
Adam Waterworth, Ashleigh Hamilton, Philip Johnston, Anna Todd, Grainne Connolly, Ailish Nugent, Paula Scullin, Sarah McKenna, Sarah Lawless, Helen Wallace, Ian Wallace
Practical Diabetes.2023; 40(3): 26. CrossRef
Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65 years) fit for cisplatin: A sub-analysis from a phase 3 study
Luigi Celio, Rupert Bartsch, Matti Aapro
Journal of Geriatric Oncology.2023; 14(6): 101537. CrossRef
Effects of Vitamin Intake on Blood Glucose in Cancer Patients Undergoing Chemotherapy: Quantitative and Descriptive Research
Ji Yeong Kim, Kyung Hee Lim
Korean Journal of Adult Nursing.2023; 35(2): 148. CrossRef
Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy
Toshinobu Hayashi, Mototsugu Shimokawa, Koichi Matsuo, Masanobu Uchiyama, Kei Kawada, Takafumi Nakano, Takashi Egawa
Oncology.2023; 101(9): 584. CrossRef
Usefulness of Indian Diabetes Risk Score in Predicting Treatment-Induced Hyperglycemia in Women Undergoing Adjuvant Chemotherapy for Breast Cancer
Krishna Prasad, Sanath Hegde, Suresh Rao, Rhea Katherine D'souza, Thomas George, Manjeshwar Shrinath Baliga, Sucharitha Suresh
South Asian Journal of Cancer.2023;[Epub] CrossRef
Prognostic Factors for Hyperglycemia in Patients Receiving Chemotherapy
Jiyeong Kim, Kyung Hee Lim
Cancer Nursing.2023;[Epub] CrossRef
COVID‐19 and dexamethasone‐induced hyperglycaemia: Workload implications for diabetes inpatient teams
Younes R. Younes, Susan Stockley, Lorna Keegan, Linda O’Donoghue, Elizabeth Yohannan, Liz Read, Jamie‐Leigh Williamson, John Peter, Kavitha Lakshmipathy, Vera Smout, Vidhu Nayyar, Julian Emmanuel, Sunil Zachariah, James Clark, Benjamin C. T. Field
Diabetic Medicine.2022;[Epub] CrossRef
The effectiveness and safety of corticosteroid therapy for IgA nephropathy with crescents: a prospective, randomized, controlled study
Mengjun Liang, Liping Xiong, Aihua Li, Jiafan Zhou, Yajuan Huang, Miaofang Huang, Xing Zhang, Hongrui Shi, Ning Su, Yi Wei, Zongpei Jiang
BMC Nephrology.2022;[Epub] CrossRef
Insulin resistance and weight gain in women treated for early stage breast cancer
Grace Makari-Judson, Richard Viskochil, Deborah Katz, Ruth Barham, Wilson C. Mertens
Breast Cancer Research and Treatment.2022; 194(2): 423. CrossRef
Cytoprotective effect of genistein against dexamethasone-induced pancreatic β-cell apoptosis
Kanchana Suksri, Namoiy Semprasert, Thawornchai Limjindaporn, Pa-thai Yenchitsomanus, Sirirat Kooptiwoot, Suwattanee Kooptiwut
Scientific Reports.2022;[Epub] CrossRef
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study
Luigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, Luigi Cavanna, Olga Martelli, Simona Carnio, Elena Collovà, Federica Bertolini, Fausto Petrelli, Alessandra Cassano, Rita Chiari, Francesca Zanelli, Salvatore Pisconti, Isabella Vittimberga, Antonietta
BMC Cancer.2022;[Epub] CrossRef
Efficacy of the Dexamethasone-Sparing Triplet Regimen for Preventing Cisplatin-Induced Emesis: a Combined Analysis
Luigi Celio, Erminio Bonizzoni, Elena Montani, Matti Aapro
Future Oncology.2022; 18(30): 3389. CrossRef
How should rheumatologists manage glucocorticoid-induced hyperglycemia?
Hiroyuki Nakamura, Yuichiro Fujieda, Akinobu Nakamura, Tatsuya Atsumi
Modern Rheumatology.2021; 31(3): 519. CrossRef
A single-arm feasibility study of gradual dose de-escalation of antiemetic dexamethasone for older patients receiving chemotherapy
Koung Jin Suh, Seonghae Yoon, Jin Won Kim, Seo Hyun Yoon, Ji-Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Jee Hyun Kim
Journal of Geriatric Oncology.2021; 12(6): 922. CrossRef
Incidence and disease course of new-onset diabetes mellitus in breast and colorectal cancer patients undergoing chemotherapy: A prospective multicenter cohort study
Eun Kyung Lee, Bokyung Koo, Yul Hwangbo, You Jin Lee, Ji Yeon Baek, Yong Jun Cha, Sun Young Kim, Sung Hoon Sim, Keun Seok Lee, In Hae Park, Hyewon Lee, Jungnam Joo, Sujeong Go, Seung Chul Heo, Min Kyong Moon
Diabetes Research and Clinical Practice.2021; 174: 108751. CrossRef
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study
Luigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, Luigi Cavanna, Olga Martelli, Simona Carnio, Elena Collovà, Federica Bertolini, Fausto Petrelli, Alessandra Cassano, Rita Chiari, Francesca Zanelli, Salvatore Pisconti, Isabella Vittimberga, Antonietta
The Oncologist.2021; 26(10): e1854. CrossRef
Potential Adverse Effects of Dexamethasone Therapy on COVID-19 Patients: Review and Recommendations
Fei Chen, Lanting Hao, Shiheng Zhu, Xinyuan Yang, Wenhao Shi, Kai Zheng, Tenger Wang, Huiran Chen
Infectious Diseases and Therapy.2021; 10(4): 1907. CrossRef
Glycemic Excursion, Adverse Drug Reactions, and Self-Management in Diabetes Patients Undergoing Chemotherapy: A Literature Review
Naoko Terao, Kumi Suzuki
Asia-Pacific Journal of Oncology Nursing.2021; 8(6): 610. CrossRef
Patient-Centered Diabetes Care of Cancer Patients
Anupam Kotwal, Yee-Ming M. Cheung, Grace Cromwell, Andjela Drincic, Houry Leblebjian, Zoe Quandt, Robert J. Rushakoff, Marie E. McDonnell
Current Diabetes Reports.2021;[Epub] CrossRef
Quercetin modulates hyperglycemia by improving the pancreatic antioxidant status and enzymes activities linked with glucose metabolism in type 2 diabetes model of rats: In silico studies of molecular interaction of quercetin with hexokinase and catalase
Sunday O. Oyedemi, Godswill Nwaogu, Chika I. Chukwuma, Olaoluwa T. Adeyemi, Motlalepula G. Matsabisa, Shasank S. Swain, Olayinka A. Aiyegoro
Journal of Food Biochemistry.2020;[Epub] CrossRef
Side Effects of Adjuvant Chemotherapy and their Impact on Outcome in Elderly Breast Cancer Patients: A Cohort Study
Valentina Zanuso, Vittorio Fregoni, Lorenzo Gervaso
Future Science OA.2020;[Epub] CrossRef
Incidence of Hyperglycemia/Secondary Diabetes in Women who have Undergone Curative Chemotherapy for Breast Cancer: First Study from India
Suresh Rao, Krishna Prasad, Soniya Abraham, Thomas George, Supreeth Kakkaje Chandran, Manjeshwar Shrinath Baliga
South Asian Journal of Cancer.2020; 09(03): 130. CrossRef
Diabetes Mellitus and Osteoporosis Correlation: Challenges and Hopes
Moein Ala, Razieh Mohammad Jafari, Ahmad Reza Dehpour
Current Diabetes Reviews.2020; 16(9): 984. CrossRef
Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin
Hiroko Minatogawa, Naoki Izawa, Takashi Kawaguchi, Tempei Miyaji, Kazuhiro Shimomura, Honda Kazunori, Hirotoshi Iihara, Yasushi Ohno, Yusuke Inada, Hitoshi Arioka, Hajime Morita, Naoya Hida, Mitsuhiro Sugawara, Chikatoshi Katada, Shuichi Nawata, Hiroo Ish
BMJ Open.2020; 10(12): e041737. CrossRef
Effect of high-dose dexamethasone on patients without diabetes during elective neurosurgery: a prospective study
Majid Alabbood, Min Ling, Kenneth Ho
Diabetology International.2019; 10(2): 109. CrossRef
Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma
Saby George, Brian I. Rini, Hans J. Hammers
JAMA Oncology.2019; 5(3): 411. CrossRef
GLUCOSE EXCHANGE DISORDERS IN PATIENTS TAKING GLUCOCORTICOSTEROIDS: FEATURES OF CLINICAL MANIFESTATIONS AND CORRECTION
Al’bert Yu. Selimov, Lyudmila N. Eliseeva, Valeriya P. Kurinnaya, Sergei P. Oranskii
Kuban Scientific Medical Bulletin.2019; 26(1): 209. CrossRef
Steroid-induced diabetes in cancer patients
Gemma Dinn
Journal of Prescribing Practice.2019; 1(12): 610. CrossRef
Hyperglycemia During Childhood Cancer Therapy: Incidence, Implications, and Impact on Outcomes
Allison Grimes, Ashraf Mohamed, Jenna Sopfe, Rachel Hill, Jane Lynch
JNCI Monographs.2019; 2019(54): 132. CrossRef
Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence
Luigi Celio, Erminio Bonizzoni, Emma Zattarin, Paolo Codega, Filippo de Braud, Matti Aapro
BMC Cancer.2019;[Epub] CrossRef
Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy
Yuka Ito, Takashi Tsuda, Hiroko Minatogawa, Sayaka Kano, Kentaro Sakamaki, Masahiko Ando, Koichiro Tsugawa, Yasuyuki Kojima, Naoki Furuya, Kunihiro Matsuzaki, Mamoru Fukuda, Sadatoshi Sugae, Ichiro Ohta, Hitoshi Arioka, Yutaka Tokuda, Kazutaka Narui, Ayak
Journal of Clinical Oncology.2018; 36(10): 1000. CrossRef
Glucocorticoid‐induced diabetes among people without diabetes: a literature review
Majid Alabbood, Min Ling, Kenneth Ho
Practical Diabetes.2018; 35(2): 63. CrossRef
Metformin prevents metabolic side effects during systemic glucocorticoid treatment
Eleonora Seelig, Stefanie Meyer, Katharina Timper, Nicole Nigro, Martina Bally, Ida Pernicova, Philipp Schuetz, Beat Müller, Marta Korbonits, Mirjam Christ-Crain
European Journal of Endocrinology.2017; 176(3): 349. CrossRef
Central pancreatectomy: an oncologically safe option to treat metastases of other neoplasms of the mid-portion of the pancreas?
Traian Dumitrascu, Andra Scarlat, Mihnea Ionescu, Irinel Popescu
Annals of Hepato-Biliary-Pancreatic Surgery.2017; 21(2): 76. CrossRef
Outpatient management of steroid-induced hyperglycaemia and steroid-induced diabetes in people with lymphoproliferative disorders treated with intermittent high dose steroids
Jennifer Vidler, Charlotte Rogers, Deborah Yallop, Stephen Devereux, Ellinor Wellving, Orla Stewart, Alison Cox, Katharine F. Hunt, Shireen Kassam
Journal of Clinical & Translational Endocrinology.2017; 9: 18. CrossRef
Consumption of Fresh Yellow Onion Ameliorates Hyperglycemia and Insulin Resistance in Breast Cancer Patients During Doxorubicin-Based Chemotherapy: A Randomized Controlled Clinical Trial
Farnaz Jafarpour-Sadegh, Vahid Montazeri, Ali Adili, Ali Esfehani, Mohammad-Reza Rashidi, Saeed Pirouzpanah
Integrative Cancer Therapies.2017; 16(3): 276. CrossRef

14,503 View
352 Download
46 Web of Science
51 Crossref

Impact of Hyperglycemia on Survival and Infection-Related Adverse Events in Patients with Metastatic Colorectal Cancer Who Were Receiving Palliative Chemotherapy: Yong Joo Hong, Hye-Suk Han, Yusook Jeong, Jiwon Jeong, Sung-Nam Lim, Hyung Jin Choi, Hyun-Jung Jeon, Tae-Keun Oh, Sang-Jeon Lee, Ki Hyeong Lee; Cancer Res Treat. 2014;46(3):288-296. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.288

Abstract PDF PubReader ePub

Purpose
Non-metastatic colorectal cancer patients with diabetes have poor overall survival than those without diabetes. However, the effect of hyperglycemia on survival after diagnosis of metastatic colorectal cancer (CRC) has not been assessed. Therefore, we assessed the impact of hyperglycemia on the survival and infection-related adverse events (AEs) in patients with metastatic CRC. Materials and Methods We reviewed the records of 206 patients with newly diagnosed metastatic CRC who were treated with palliative chemotherapy from March 2000 to December 2012 at Chungbuk National University Hospital. The mean glucose level of each patient was calculated using all available glucose results. Results The mean glucose levels ranged between 76.8 and 303.5 mg/dL, and patients were categorized into quartiles in accordance to their mean glucose level: group 1 (< 106.7 mg/dL), group 2 (106.7-117.2 mg/dL), group 3 (117.3-142.6 mg/dL), and group 4 (> 142.6 mg/dL). The median overall survival for patients in groups 1, 2, 3, and 4 were 22.6, 20.1, 18.9, and 17.9 months, respectively; however, this difference was not statistically significant (p=0.643). Compared with patients in group 1, those in groups 2, 3, and 4 were at a higher risk of infection-related AEs, according to a multivariate analysis (p=0.002). Conclusion Hyperglycemia was not associated with shorter survival; however, it was associated with infection-related AEs in patients with newly diagnosed metastatic CRC receiving palliative chemotherapy.

Citations

Citations to this article as recorded by

Glucocorticoid-Induced Hyperglycemia in Oncologic Outpatients: A Narrative Review Using the Quadruple Aim Framework
Ihab Kandil, Erin Keely
Canadian Journal of Diabetes.2022; 46(7): 730. CrossRef
Association of Comorbid Diabetes With Clinical Outcomes and Healthcare Utilization in Colorectal Cancer Survivors
Susan Storey, Zuoyi Zhang, Xiao Luo, Diane Von Ah, Megan Metzger, Jie Zhang, Amrutha Jakka, Kun Huang
Oncology Nursing Forum.2021; 48(2): 195. CrossRef
The influence on survival of glucocorticoid induced diabetes in cancer patients with metastatic spinal cord compression
Helga Schultz, Ulrik Pedersen-Bjergaard, Andreas Kryger Jensen, Svend Aage Engelholm, Peter Lommer Kristensen
Clinical and Translational Radiation Oncology.2018; 11: 19. CrossRef
Measurement of Hyperglycemia and Impact on Health Outcomes in People With Cancer: Challenges and Opportunities
Susan Storey, Diane Ah, Marilyn Hammer
Oncology Nursing Forum.2017; 44(4): E141. CrossRef
Glycemic modulation in neuro-oncology: experience and future directions using a modified Atkins diet for high-grade brain tumors
Roy E. Strowd, Mackenzie C. Cervenka, Bobbie J. Henry, Eric H. Kossoff, Adam L. Hartman, Jaishri O. Blakeley
Neuro-Oncology Practice.2015; 2(3): 127. CrossRef
The Role of Glucose Modulation and Dietary Supplementation in Patients With Central Nervous System Tumors
Roy E. Strowd, Stuart A. Grossman
Current Treatment Options in Oncology.2015;[Epub] CrossRef

11,957 View
72 Download
7 Web of Science
6 Crossref

Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion: Yoon Mi Shin, Jieun Yun, Ok-Jun Lee, Hye-Suk Han, Sung-Nam Lim, Jin Young An, Ki Hyeong Lee, Ki Man Lee, Kang Hyeon Choe; Cancer Res Treat. 2014;46(2):178-185. Published online April 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.2.178

Abstract PDF PubReader ePub

Purpose

The accurate and timely diagnosis of malignant pleural effusion (MPE) in lung cancer patients is important because MPE has a poor prognosis and is classified as stage IV disease. Molecular biomarkers for pleural effusion, such as circulating extracellular microRNAs (miRNAs) isolated from pleural fluid, may help in the diagnosis of MPE. The present study examined whether miRNAs that are deregulated in lung cancer (miR-134, miR-185, and miR-22) can serve as diagnostic markers for lung adenocarcinoma-associated MPE (LA-MPE).

Materials and Methods

Real-time reverse transcription quantitative polymerase chain reaction was used to measure the expression of the three miRNAs in samples from 87 patients with pleural effusion comprising 45 LA-MPEs and 42 benign pleural effusions (BPEs). The area under the receiver operating characteristic curve (AUC) was then used to evaluate the diagnostic performance of each of the three miRNAs and compare it with that of the common tumor marker, carcinoembryonic antigen (CEA).

Results

The expression of all three miRNAs was significantly lower in LA-MPE than in BPE (p <0.001). The AUCs for miR-134, miR-185, miR-22, and CEA were 0.721, 0.882, 0.832, and 0.898, respectively. Combining CEA with the three miRNAs increased the diagnostic performance, yielding an AUC of 0.942 (95% confidence interval, 0.864 to 0.982), with a sensitivity of 91.9% and a specificity of 92.5%.

Conclusion

The present study suggests that the expression levels of circulating extracellular miR-134, miR-185, and miR-22 in patients with pleural effusion may have diagnostic value when differentiating between LA-MPE and BPE.

Citations

Citations to this article as recorded by

Key methodological challenges in detecting circulating miRNAs in different biofluids
Chitra Mestry, Tester F Ashavaid, Swarup AV Shah
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine.2023; 60(1): 14. CrossRef
MiRNAs in Lung Adenocarcinoma: Role, Diagnosis, Prognosis, and Therapy
Yongan Song, Leonardo Kelava, István Kiss
International Journal of Molecular Sciences.2023; 24(17): 13302. CrossRef
High Diagnostic and Prognostic Value of miRNAs Compared with the Carcinoembryonic Antigen As A Traditional Tumor Marker
Neda Yaghoubi , Farnaz Zahedi Avval , Majid Khazaei, Amirhossein Sahebkar , Seyed Hamid Aghaee-Bakhtiari
Anti-Cancer Agents in Medicinal Chemistry.2022; 22(2): 206. CrossRef
Diagnostic utility of pleural cell-free nucleic acids in undiagnosed pleural effusions
Wen Zhao, Xi-Shan Cao, Yu-Ling Han, Xu-Hui Wen, Wen-Qi Zheng, Zhi-De Hu
Clinical Chemistry and Laboratory Medicine (CCLM).2022; 60(10): 1518. CrossRef
Construction and analysis of expression profile of exosomal lncRNAs in pleural effusion in lung adenocarcinoma
Xiaolu Huang, Huixin Zhou, Xiang Yang, Wenjing Shi, Lijuan Hu, Junjun Wang, Fan Zhang, Fanggui Shao, Meijuan Zhang, Feng Jiang, Yumin Wang
Journal of Clinical Laboratory Analysis.2022;[Epub] CrossRef
Molecular testing on serous effusions
Ben Davidson
Diagnostic Cytopathology.2021; 49(5): 640. CrossRef
Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions
Maria Alba Sorolla, Anabel Sorolla, Eva Parisi, Antonieta Salud, José M. Porcel
Cancers.2021; 13(11): 2798. CrossRef
Four plasma miRNAs act as biomarkers for diagnosis and prognosis of non‑small cell lung cancer
He-Guo Jiang, Chun-Hua Dai, Ya-Ping Xu, Qian Jiang, Xian-Bin Xia, Yang Shu, Jian Li
Oncology Letters.2021;[Epub] CrossRef
Molecular testing on serous effusion: An update
Saumya Sahu, Parikshaa Gupta, Pranab Dey
Cytojournal.2021; 18: 35. CrossRef
Non-coding RNA and lung cancer progression
Afeez Adekunle Ishola, Anita Silas La’ah, Hung Dinh Le, Viet Quoc Nguyen, Yi-Ping Yang, Shih-Jie Chou, Hsiao-Yun Tai, Chian-Shiu Chien, Mong-Lien Wang
Journal of the Chinese Medical Association.2020; 83(1): 8. CrossRef
Role of microRNAs as Clinical Cancer Biomarkers for Ovarian Cancer: A Short Overview
Cristina Elena Staicu, Dragoș-Valentin Predescu, Călin Mircea Rusu, Beatrice Mihaela Radu, Dragos Cretoiu, Nicolae Suciu, Sanda Maria Crețoiu, Silviu-Cristian Voinea
Cells.2020; 9(1): 169. CrossRef
microRNA exchange via extracellular vesicles in cancer
Luyen Tien Vu, Jinhua Gong, Thach Tuan Pham, Yeokyeong Kim, Minh T. N. Le
Cell Proliferation.2020;[Epub] CrossRef
MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions
Kimberly A. Birnie, Cecilia M. Prêle, Arthur W. (Bill) Musk, Nicholas de Klerk, Y. C. Gary Lee, Deirdre Fitzgerald, Richard J. N. Allcock, Philip J. Thompson, Jenette Creaney, Bahareh Badrian, Steven E. Mutsaers
Disease Markers.2019; 2019: 1. CrossRef
Combination of DNA ploidy analysis and miR-21 or miR-24 in screening malignant pleural effusion
Chongmei Liu, Liuyan Huang, Xuechun Zhang, Juan Yang
Interactive CardioVascular and Thoracic Surgery.2018; 26(3): 376. CrossRef
Microarray expression profile and analysis of circular RNA regulatory network in malignant pleural effusion
Yakun Wen, Yong Wang, Zhenchuan Xing, Zongjian Liu, Ziliang Hou
Cell Cycle.2018; 17(24): 2819. CrossRef
Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis
Mei Feng, Jing Zhu, Liqun Liang, Ni Zeng, Yanqiu Wu, Chun Wan, Yongchun Shen, Fuqiang Wen
International Journal of Clinical Oncology.2017; 22(2): 283. CrossRef
miR-134: A Human Cancer Suppressor?
Jing-Yu Pan, Feng Zhang, Cheng-Cao Sun, Shu-Jun Li, Guang Li, Feng-Yun Gong, Tao Bo, Jing He, Rui-Xi Hua, Wei-Dong Hu, Zhan-Peng Yuan, Xin Wang, Qi-Qiang He, De-Jia Li
Molecular Therapy - Nucleic Acids.2017; 6: 140. CrossRef
Molecular mechanisms and clinical applications of miR-22 in regulating malignant progression in human cancer (Review)
Jingyu Wang, Yuan Li, Meiman Ding, Honghe Zhang, Xiaoming Xu, Jinlong Tang
International Journal of Oncology.2017; 50(2): 345. CrossRef
MicroRNA-134 modulates glioma cell U251 proliferation and invasion by targeting KRAS and suppressing the ERK pathway
Yuguang Zhao, Dong Pang, Cui Wang, Shijiang Zhong, Shuang Wang
Tumor Biology.2016; 37(8): 11485. CrossRef
MicroRNA profiling of cisplatin-resistant oral squamous cell carcinoma cell lines enriched with cancer-stem-cell-like and epithelial-mesenchymal transition-type features
Ruma Dey Ghosh, Sangeeta Ghuwalewala, Pijush Das, Sapan Mandloi, Sk Kayum Alam, Jayanta Chakraborty, Sajal Sarkar, Saikat Chakrabarti, Chinmoy Kumar Panda, Susanta Roychoudhury
Scientific Reports.2016;[Epub] CrossRef
Cell‐free microRNAs in blood and other body fluids, as cancer biomarkers
Blanca Ortiz‐Quintero
Cell Proliferation.2016; 49(3): 281. CrossRef
Clinical relevance of circulating cell-free microRNAs in ovarian cancer
Koji Nakamura, Kenjiro Sawada, Akihiko Yoshimura, Yasuto Kinose, Erika Nakatsuka, Tadashi Kimura
Molecular Cancer.2016;[Epub] CrossRef
MicroRNA-432 functions as a tumor suppressor gene through targeting E2F3 and AXL in lung adenocarcinoma
Ling Chen, Guangming Kong, Chuantao Zhang, Hongyan Dong, Cuicui Yang, Guanhua Song, Chengye Guo, Lin Wang, Hongsheng Yu
Oncotarget.2016; 7(15): 20041. CrossRef
Hepatocellular carcinoma and microRNA: New perspectives on therapeutics and diagnostics
Ningning Yang, Nsikak R. Ekanem, Clement A. Sakyi, Sidhartha D. Ray
Advanced Drug Delivery Reviews.2015; 81: 62. CrossRef
Reduced expression of microRNA-134 correlates with malignancy and poor prognosis in human glioma
Jianfeng Zhong, Bing Li
Journal of Clinical Neuroscience.2015; 22(3): 583. CrossRef
2015 update on the diagnosis and management of neoplastic pericardial disease
Chiara Lestuzzi, Massimiliano Berretta, Witold Tomkowski
Expert Review of Cardiovascular Therapy.2015; 13(4): 377. CrossRef
Extracellular microRNAs in bronchoalveolar lavage samples from patients with lung diseases as predictors for lung cancer
Grit Rehbein, Bernd Schmidt, Michael Fleischhacker
Clinica Chimica Acta.2015; 450: 78. CrossRef

16,024 View
136 Download
38 Web of Science
27 Crossref

Case Reports

Multiple Cardiac Metastases from a Nonfunctioning Pancreatic Neuroendocrine Tumor: Yong Hyeok Choi, Hye-Suk Han, Sung-Nam Lim, Sang Yeub Lee, Ji Hae Koo, Ok-Jun Lee, Ki Hyeong Lee, Seung Taik Kim; Cancer Res Treat. 2013;45(2):150-154. Published online June 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.2.150

Abstract PDF PubReader ePub

Pancreatic neuroendocrine tumors (pNETs) are rare neoplasms, which most commonly metastasize to the liver. However, intrathoracic metastases from pNETs are encountered infrequently. This report describes a case of nonfunctioning pNET with multiple cardiac metastases. A 56-year-old male presented with a palpable abdominal mass that showed progressive enlargement. Findings on computed tomography (CT) of the abdomen revealed two relatively well-marginated inhomogeneous low-attenuation masses, one in the head of the pancreas and the other in the tail. Multiple enhancing masses in the left pericardium with myocardial involvement were observed on chest CT and transthoracic echocardiography. Needle biopsies were performed on the mass in the tail of the pancreas and the left ventricular apical pericardium; histologic examination by hematoxylin and eosin morphology and immunohistochemical staining showed pNET in both. This is the first report of pNET with multiple cardiac metastases to previously undescribed metastatic sites.

Citations

Citations to this article as recorded by

Cardiac Neuroendocrine Tumor Metastases on68Ga-DOTATATE PET/CT: Identification and Prognostic Significance
Hwan Lee, Ahmad S. Alhamshari, Vandan Patel, Abhijit Bhattaru, Chaitanya Rojulpote, Mahesh K. Vidula, Daniel A. Pryma, Paco E. Bravo
Journal of Nuclear Medicine.2024; 65(11): 1745. CrossRef
Atypical Cardiac Location of Melanoma of Unknown Origin
Agnieszka Styczeń, Mariusz Kozak, Marta Karaś-Głodek, Elżbieta Czekajska-Chehab, Andrzej Tomaszewski, Andrzej Wysokiński, Tomasz Zapolski
Medicina.2021; 57(2): 107. CrossRef
Cardiac Metastases in Patients with Neuroendocrine Tumours: Clinical Features, Therapy Outcomes, and Prognostic Implications
Man Liu, Eleni Armeni, Shaunak Navalkissoor, Joseph Davar, Luke Sullivan, Charlotte Leigh, Luke Furtado O’Mahony, Aimee Hayes, Dalvinder Mandair, Jie Chen, Martyn Caplin, Christos Toumpanakis
Neuroendocrinology.2021; 111(10): 907. CrossRef
A concealed carcinoid cardiac metastasis uncovered by comprehensive cardiovascular magnetic resonance-based tissue characterization: a case report
Georgios Georgiopoulos, Panagiota Mitropoulou, Pier Giorgio Masci, Juerg Schwitter, Khan Tina, Voges Inga, Raisi Estabragh Zahra, Minguito Carazo Carlos, Thomson Ross
European Heart Journal - Case Reports.2020; 4(6): 1. CrossRef
A Multimodal Approach to Evaluate for Cardiac Metastasis in a Case of Non-Small Cell Lung Cancer
Nadeem Bilani, Leah Elson, Felipe Martinez, Diego Sadler, Zeina Nahleh, Elizabeth Elimimian, Evan Alley
Case Reports in Oncology.2020; 13(1): 212. CrossRef
Identification of multiple cardiac metastases from nonsmall-cell lung cancer by 18F-FDG PET/CT
Shengming Deng, Bin Zhang, Jihui Li, Shibiao Sang, Wei Zhang
Medicine.2018; 97(49): e12868. CrossRef

12,036 View
67 Download
6 Crossref

Poorly Differentiated Neuroendocrine Carcinoma in a Perigastric Lymph Node from an Unknown Primary Site: Hee Seung Lee, Hye-Suk Han, Sung-Nam Lim, Hyun-Jung Jeon, Ho-chang Lee, Ok-Jun Lee, Hyo Young Yun, Ki Hyeong Lee, Seung Taik Kim; Cancer Res Treat. 2012;44(4):271-274. Published online December 31, 2012; DOI: https://doi.org/10.4143/crt.2012.44.4.271

Abstract PDF PubReader ePub

Neuroendocrine carcinomas from an unknown primary site are uncommon. The authors report on a case of neuroendocrine carcinoma in a perigastric lymph node (LN) with no primary site. A 52-year-old male patient with early gastric adenocarcinoma underwent treatment by endoscopic submucosal dissection, and, six months later, findings on a computed tomographic scan of the abdomen revealed a LN enlargement measuring 2.0 cm in the perigastric region. The patient underwent subtotal gastrectomy and regional LN dissection under a suggestive preoperative diagnosis of gastric adenocarcinoma with LN metastasis. However, microscopically, no residual tumor was found in the stomach, and the perigastric LN showed poorly differentiated neuroendocrine carcinoma (PDNEC). After an extensive workup, no primary site was identified. The patient also received four cycles of etoposide and cisplatin. Despite its extremely rare incidence, this case suggests that PDNEC of an unknown primary site is limited to a single site, and that resection should be considered in combination with chemotherapy.

Citations

Citations to this article as recorded by

A case of laparoscopic lymphadenectomy for adenocarcinoma of unknown primary incidentally detected as a solitary enlarged lymph node along the common hepatic artery
Tomonori Morimoto, Shigeo Hisamori, Hiromitsu Kinoshita, Yosuke Yamada, Yuki Teramoto, Takashi Sakamoto, Keiko Kasahara, Shintaro Okumura, Tatsuto Nishigori, Shigeru Tsunoda, Kazutaka Obama
Surgical Case Reports.2024;[Epub] CrossRef
Synchronous Gastric Adenocarcinoma and Perigastric Lymph Node Metastatic Squamous Cell Carcinoma with Unknown Primary: A Case Report
Bernard K Seshie, Ki Hyun Kim, Hyun Jung Lee, Si Hak Lee, Sun-Hwi Hwang
The Journal of Minimally Invasive Surgery.2020; 23(2): 99. CrossRef
Metastatic Neuroendocrine Carcinoma of Unknown Origin Arising in the Femoral Nerve Sheath
Nicholas Candy, Adam Young, Kieren Allinson, Oliver Carr, Jason McMillen, Rikin Trivedi
World Neurosurgery.2017; 104: 1047.e1. CrossRef
Submucosal small-cell neuroendocrine carcinoma of the larynx detected using 18F-fluorodeoxyglucose positron emission tomography/computed tomography: A case report and review of the literature
HONG-FANG YING, YANG-YANG BAO, SHUI-HONG ZHOU, LIANG CHAI, KUI ZHAO, TING-TING WU
Oncology Letters.2014; 8(3): 1065. CrossRef

11,136 View
49 Download
4 Crossref

Metastatic Renal Cell Carcinoma in a Supraclavicular Lymph Node with No Known Primary: A Case Report: Young-Rak Choi, Hye-Suk Han, Ok-Jun Lee, Sung-Nam Lim, Mi-Jin Kim, Myeong-Ho Yeon, Hyun-Jung Jeon, Ki Hyeong Lee, Seung Taik Kim; Cancer Res Treat. 2012;44(3):215-218. Published online September 30, 2012; DOI: https://doi.org/10.4143/crt.2012.44.3.215

Abstract PDF PubReader ePub

Although metastasis is relatively frequent in cases of renal cell carcinoma (RCC), metastasis in the cervical or supraclavicular lymph node (LN) is relatively rare. Moreover, cases of metastatic RCC with a non-identifiable kidney mass are extremely rare. Here, the authors report a case of metastatic RCC in a supraclavicular LN without a primary kidney lesion. A 69-year-old man presented with a progressively enlarging right supraclavicular mass. Incisional biopsy of the affected supraclavicular LN was performed, and histological examination revealed metastatic RCC. However, no tumor was found in either kidney, despite various examinations. The patient was treated with radiotherapy followed by sunitinib. After three months on sunitinib, a follow-up computed tomography scan revealed that the supraclavicular LN had markedly decreased, and after 20 months, the disease had not progressed. This case suggests that, even when there is no primary kidney lesion, clinicians must consider the possibility of metastatic RCC when evaluating patients with clear cell carcinoma with an unknown primary site.

Citations

Citations to this article as recorded by

Pure Metastatic Papillary Renal Cell Carcinoma Without Renal Mass: A Case Report and Literature Review
Pay Enes, Ibrahim Hacibey, Serhat Yentur, Salih Sonmez, Atilla Semercioz
International Journal of Clinical and Experimental Medical Sciences.2024; 10(2): 25. CrossRef
Nivolumab rechallenge after severe immune hepatitis in a metastatic renal cell cancer patient with hepatitis B and no detectable primary
Lutfiye Demir, Funda Canaz
Indian Journal of Cancer.2023; 60(1): 114. CrossRef
Extrarenal renal cell carcinoma arising in the kidney proximity but without an identifiable renal primary – an intriguing dilemma: report of three cases and review of the literature
Mehdi Mansoor, Morgan Young‐Speirs, Bing Ren, Geoffrey Gotto, Larissa Merten, Summit Sawhney, Farshid Siadat, Andres M Acosta, Abbas Agaimy, Kiril Trpkov
Histopathology.2022; 81(5): 635. CrossRef
New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?
Elie Rassy, Pauline Parent, Felix Lefort, Stergios Boussios, Giulia Baciarello, Nicholas Pavlidis
Critical Reviews in Oncology/Hematology.2020; 147: 102882. CrossRef
Metastatic renal cell carcinoma of unknown primary site. Clinical follow-up
N. A. Ognerubov, T. S. Antipova, G. E. Gumareva
Journal of Modern Oncology.2020; 22(3): 149. CrossRef
Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature
Anders Overby, Lone Duval, Morten Ladekarl, Britt Elmedal Laursen, Frede Donskov
Clinical Genitourinary Cancer.2019; 17(1): e32. CrossRef
Central pancreatectomy in portal annular pancreas for metastatic renal cell carcinoma: a case report
Hiroshi Yamaguchi, Yasutoshi Kimura, Minoru Nagayama, Masafumi Imamura, Shingo Tanaka, Makoto Yoshida, Eiji Yoshida, Hiroki Fujino, Takashi Machiki, Koji Miyanishi, Toru Mizuguchi, Junji Kato, Ichiro Takemasa
World Journal of Surgical Oncology.2019;[Epub] CrossRef
Metastatic renal cell carcinoma with undetectable renal mass presenting as lymphadenopathy
Mohamed Salah Fayaz, Aishah Ebrahim Al-Qaderi, Mustafa Shawki El-Sherify
CEN Case Reports.2017; 6(1): 36. CrossRef
The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future
Lisanne C. Hamming, Ben J. Slotman, Henk M. W. Verheul, Victor L. Thijssen
Angiogenesis.2017; 20(2): 217. CrossRef
Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction
Esther A. Kleibeuker, Matthijs A. ten Hooven, Kitty C. Castricum, Richard Honeywell, Arjan W. Griffioen, Henk M. Verheul, Ben J. Slotman, Victor L. Thijssen
Cancer Medicine.2015; 4(7): 1003. CrossRef
Combining radiotherapy with sunitinib: lessons (to be) learned
Esther A. Kleibeuker, Matthijs A. ten Hooven, Henk M. Verheul, Ben J. Slotman, Victor L. Thijssen
Angiogenesis.2015; 18(4): 385. CrossRef
Sunitinib

Reactions Weekly.2014; 1494(1): 42. CrossRef
To combine or not combine: the role of radiotherapy and targeted agents in the treatment for renal cell carcinoma
Christian Weiss, Björn Schulze, Annette Ottinger, Claus Rödel
World Journal of Urology.2014; 32(1): 59. CrossRef

12,903 View
99 Download
13 Crossref

Original Articles

Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil and Low Dose Leucovorin in Patients with Advanced Colorectal Cancer: Yoon Mi Shin, Hae Suk Han, Seong Woo Lim, Byung Chul Kim, Kyung Suck Cheoi, Young Ook Eum, Seung Taek Kim, Ki Hyeong Lee; Cancer Res Treat. 2005;37(5):284-289. Published online October 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.5.284

Abstract PDF PubReader ePub

Purpose

The aim of this study was to evaluate the efficacy and tolerability of the oxaliplatin, 5-fluorouracil (5-FU) and low dose leucovorin (LV) combination in patients with advanced colorectal cancer.

Materials and Methods

Patients with unresectable or recurrent colorectal carcinomas were prospectively accrued. Up to one prior chemotherapy regimen was allowed. Patients received oxaliplatin, 85 mg/m², administered as a 2-hour infusion on day 1, followed by LV, 20 mg/m², as a bolus and 5-FU, 1,500 mg/m², via continuous infusion for 24 hours on days 1 and 2. Treatment was repeated every 2 weeks until disease progression or adverse effects prohibited further therapy.

Results

Between August 1999 and May 2004, 31 patients were enrolled in this study. Of the patients enrolled, 24 and 31 were evaluable for tumor response and survival analysis, respectively. The patients' characteristics included a median age of 59, with 6 (19%) having had prior chemotherapy. No patient achieved a complete response, but nine (38%) attained a partial response. Seven (29%) patients maintained a stable disease and 8 (33%) experienced increasing disease. The median duration of the response was 6 months. After a median follow-up of 9.6 months, the median time to progression was 3.8 months, with a median survival of 10.7 months. The hematological toxicities were mild to moderate, with no treatment-related mortality or infection. The major non-hematological toxicity was gastrointestinal toxicity.

Conclusion

The combination chemotherapy of oxaliplatin, low dose LV and continuous infusion of 5-FU is safe and has a cost-benefit, but is a moderately effective regimen in advanced colorectal cancer. A randomized trial comparing low and high dosages of leucovorin in the FOLFOX regimen is warranted.

Citations

Citations to this article as recorded by

Extracellular vesicles derived from Lactobacillus plantarum restore chemosensitivity through the PDK2-mediated glucose metabolic pathway in 5-FU-resistant colorectal cancer cells
JaeJin An, Eun-Mi Ha
Journal of Microbiology.2022; 60(7): 735. CrossRef
Prognostic and Predictive Role of Excision Repair Cross-complementation Group 1 and Thymidylate Synthase in Colorectal Carcinoma Patients Received FOLFOX Chemotherapy: An Immunohistochemical Study
Dalia M. Badary, Mai M. Elkabsh, Hussam H. Mady, Adel Gabr, Sana S. Kroosh
Applied Immunohistochemistry & Molecular Morphology.2020; 28(10): 741. CrossRef
Outpatient-basis Chemotherapy of Oxaliplatin, 5-fluorouracil, and Leucovorin as First-line Treatment for Patients with Metastatic or Recurrent Colorectal Cancer
Joon Ho Moon, Jong Gwang Kim, Sang Kyun Sohn, Jin Ho Baek, Yoon Young Cho, Yee Soo Chae, Byung Min Ahn, Shi Nae Kim, Soo Jung Lee, In Taek Lee, Gyu Seog Choi, Soo Han Jun
Journal of Korean Medical Science.2007; 22(3): 400. CrossRef

8,763 View
53 Download
3 Crossref

Concurrent FP (5-fluorouracil, cisplatin) Chemoradiotherapy for Patients with Esophageal Cancer: Min Ok Kim, Eui Sil Hong, Ji Young Chai, Joung Muk Leem, Il Young You, Won Dong Kim, Woo Yoon Park, Seung Taik Kim, Ki Hyeong Lee; Cancer Res Treat. 2003;35(4):330-334. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.330

Abstract PDF

PURPOSE
The outcomes of a surgical approach for patients with an esophageal carcinoma remain unsatisfactory despite its high complication rates. We conducted a phase II trial, using combined FP (5-fluorouracil and cisplatin) chemotherapy and concurrent radiotherapy, as a definitive therapy for patients with esophageal cancer.
MATERIALS AND METHODS
Patients with histologically proven esophageal cancer were enrolled onto this study. The treatment consisted of four courses of chemotherapy and six and a half weeks of radiotherapy. The patients received chemotherapy in weeks 1, 5, 12 and 16 (5-fluorouracil 1, 000 mg/m2 on days 1 to 4 and cisplatin 75 mg/m2 on day 1). Radiotherapy was administered at a dose of 59.4 Gy, in five 1.8 Gy fractions a week.
RESULTS
A total of 22 eligible patients entered the study. Of the 19 evaluable patients, a complete response occurred in 7 (37%), and a partial response in 8 (42%). After a median follow-up of 35 months, the overall survival rate was 32% at three years and the median survival was 11 months. Fourteen (64%) received planned dose of radio-therapy and 13 (59%) received more than three courses of chemotherapy. However, there was no difference in three-year survival rates between the patients that received less than three courses of chemotherapy and those that received three or more courses (31% vs. 32%). The major treatment related toxicity was mucositis, which developed in every patient, with grades III or IV in thirteen (59%) patients. During the treatment, the patients lost, on average, 3.8% of their body weight. The mean hospital stay was 23 days, with a total duration of treatment of 74 days.
CONCLUSIONS
Concurrent FP chemoradiotherapy was effective as a definitive therapy for patients with esophageal cancer. The major toxicity was mucositis. Although the treatment was relatively feasible, a randomized trial of reduced courses of chemotherapy is warranted.

Citations

Citations to this article as recorded by

Anti-cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma through Down-Regulation of COX-2 mRNA and PGE₂
Ivan Ho Yuen Pun, Dessy Chan, Sau Hing Chan, Po Yee Chung, Yuan Yuan Zhou, Simon Law, Alfred King Yin Lam, Chung Hin Chui, Albert Sun Chi Chan, Kim Hung Lam, Johnny Cheuk On Tang
Cancer Research and Treatment.2017; 49(1): 219. CrossRef
Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer
Sang-Hee Cho, Ik-Joo Chung, Sang-Yun Song, Deok-Hwan Yang, Jeong-Rae Byun, Yeo-Kyeoung Kim, Je-Jung Lee, Kook-Joo Na, Hyeoung-Joon Kim
Journal of Korean Medical Science.2005; 20(4): 618. CrossRef

4,684 View
29 Download
2 Crossref

5-Fluorouracil and Cisplatin (FP) with Concurrent Radiotherapy for Locally Advanced Head and Neck Cancer: Hyoung Sam Kim, Ki Seok Kim, Sang Seok Bea, Seok Jin Oh, Ki Hyeong Lee, Won Dong Kim, Woo Yoon Park, Seung Taik Kim; Cancer Res Treat. 2002;34(4):296-301. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.296

Abstract PDF

The combination of chemotherapy and radiotherapy is emerging as the new standard modality for the treatment of locally advanced head and neck cancer, due to the inherent functional and cosmetic sequelae associated with its surgical management. Combination chemotherapy with 5-fluorouracil and cisplatin (FP) is one of the most active regimens for the head and neck cancer. Furthermore, both agents are known to act as radiosensitizer. This study was conducted to determine the efficacy, feasibility, and the toxicities of concurrent FP chemotherapy with radiotherapy.
MATERIALS AND METHODS
Patients with histologically proven locally advanced head and neck cancer (T3-4 or node positive) were enrolled in the study. Patients received 5-fluorouracil, 1,000 mg/m2/day, continuously for 4 days, and cisplatin, 75 mg/m2, on day 1. This regimen was given every four weeks. The radiotherapy (45 Gy) was started on day 1 of the first cycle, and administered in 25 fractions. Following a three-week interval, the radiotherapy was resumed on day 1 of the third cycle of chemotherapy, and administered in 15 fractions (27 Gy).
RESULTS
Of the 31 eligible patients included, 28 were able to be evaluated for the tumor response. The response rate for the 28 patients was 93% (16 complete responses, 10 partial responses). Disease free survival for the 16 complete responders was 37 months (median, 1 ~41 months), with a median follow-up time of 31 months. The 1-, 2-, and 3-year survival rates were 82%, 69%, and 63%, respectively. Regarding the feasibility of this treatments, only nineteen patients (61%) received the complete courses of scheduled treatments. The median duration of admission for all patients was 39 days. Grade 3 or 4 stomatitis were observed in 25 patients (83%) and appeared as the dose limiting toxicity of this regimen CONCLUSION: Although FP chemotherapy with concurrent radiotherapy is toxic, it is an effective and relatively feasible treatment for locally advanced head and neck cancer. The majority of patients experienced severe stomatitis, which appeared as the dose limiting toxicity of this regimen.

Citations

Citations to this article as recorded by

Chemotherapy of Head and Neck Cancer
Chang Ki Yeo
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2014; 57(5): 291. CrossRef

4,826 View
32 Download
1 Crossref

Clinical Characteristics and Prognostic Factors of Metastatic Tumor of Unknown Primary: Eun Kyung Cho, Keun Seok Lee, Chul Won Jung, Won Seog Kim, Ki Hyeong Lee, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1999;31(3):607-616.

Abstract PDF: PURPOSE
For malignant diseases, predictions about tumor behavior and determination of appropriate therapy are based on the primary tumor sites, but 2-9% of cancer patients are diagnosed without identifiable primary tumor sites. Metastatic tumors of unknown primary origin (MUO) are a heterogeneous group of tumors with variable natural histories. The majority of these patients fall outside of treatable subjects and seldom respond to therapy. To define further the natural history of MUO and identify prognostic factors, we undertook a clinical analysis of 141 consecutive patients with a presumed diagnosis of MUO.
MATERIALS AND METHODS
One hundred forty-one patients were diagnosed with unknown primary tumor from Jan. 1, 1992 through Aug. 31, 1995. The primary end point for the study was survival, which was calculated from the first day of patient registration diagnosed histologically. The survival curves were estimated using the Kaplan-Meier method and compared using the log-rank test. To identify important prognostic factors, univariate and multivariate analyses were conducted.
RESULTS
Most of the 141 patients had histologic or cytologic evidence of adenocarcinoma and had more than one site metastatically involved. The predominant sites of tumor involvement were lymph node, peritoneum, bone, liver, lung, and pleura. Univariate and multivariate analyses identified numerous important prognostic factors with a significant influence on survival, including performance status (P 0.0001), specific organ sites involved (lung P 0.0076 or liver P 0.0310), and chemotherapy group (P- 0.0480).
CONCLUSION
This study validated clinical courses and important prognostic factors that had an impact on survival in MUO.

2,663 View
14 Download

IMVP-16/Pd (Ifosfamide/Methotrexate/VP-16/Prednisone) Combination Chemotherapy for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma: Ki Hyeong Lee, Young Iee Park, Heung Moon Chang, Tae You Kim, Keong Hae Jung, In Suk Woo, Young Hyuck Im, Dae Seog Heo, Yung Jue Bang, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1997;29(3):486-494.

Abstract PDF: PURPOSE
IMVP-16 (Ifosfamide/Methotrexate/VP-16) regimen consists of drugs that are not commonly used as the first-line therapy of non-Hodgkin's lymphoma. This study was performed to determine the efficacy of this relatively non-cross resistant regimen, with the addition of prednisone, in patients with primary refractory or relapsed non-Hodgkin's lymphoma.
MATERIALS AND METHODS
Patients with primary refractory or relpased intermediate to high grade non-Hodgkin's lymphoma were treated with ifosfamide (1000 mg/m2 iv, D1-5 with mesna), methotrexate (30 mg/m2 iv, D 3 & 10), VP-16 (100 mg/m2 iv, D 1-3), and prednisone (120 mg devided by 3 doses, D1-5). The treatment was repeated every 3 weeks.
RESULTS
Between Jan. 1988 and Aug. 1993, thirty eight patients were included. In 33 evaluable patients (4 loss-to follow up and 1 ineligibility) the median age was 49 years. The common histologic types were diffuse large cell type (52%) and immunoblastic type (18%). The proportion of patients with relapsed and refractory NHL was 39% and 61%, respectively. The rate of complete remission was 21% (7/33) and overall response rate was 48% (16/33). The median-response duration was 8 months (1.5~45+). Hematologic toxicities were tolerable. Non-hematologic side effects were also tolerable including stomatitis, peripheral neuropathy, and toxic hepatitis. Three treatment-related deaths were associated with sepsis, ARDS (adult respiratory distress syndrome) and acute gastrointestinal bleeding.
CONCLUSION
Based on these results, IMVP-16/Pd combination chemotherapy seems to have a moderate efficacy for the relapsed or refractory non-Hodgkin's lymphoma with tolerable toxicities.

4,371 View
68 Download

A prospective randomized study of cisplatin versus PEV(cisplatin, etoposide, vinblastine) chemotherapy in advanced non-small cell lung cancer: Ki Hyeong Lee, Won Ki Kang, Joung Soon Jung, Sung Soo Yoon, Young Hyuk Im, Jae Yong Lee, Young Suk Park, Chang In Suh, Dae Seog Heo, Yung Jue Bang, Young Soo Shim, Noe Kyeong Kim; J Korean Cancer Assoc. 1992;24(2):256-267.

Abstract PDF: No abstract available.

2,341 View
22 Download

5-fluorouracil, epirubicin, cisplatin(FEP) and 5-fluorouracil, cisplatin(FP) combination chemotherapy for advanced pancreatic carcinoma: Ki Hyeong Lee, Won Ki Kang, Chang In Suh, Young Suk Park, Heung Tae Kim, Yoon Koo Kang, Hyo Jin Kim, Dae Seog Heo, Yung Jue Bang, Yong Bum Yoon, Noe Kyeong Kim, Yong Hyun Park; J Korean Cancer Assoc. 1991;23(2):315-322.

Abstract PDF: No abstract available.

2,523 View
26 Download

Combination Chemotherapy with 5-Fluorouracil and Carboplatin for Advanced Head and Neck Cancer: Eun Kyung Cho, Won Sup Lee, Chul Won Jung, Keun Seok Lee, Won Seog Kim, Ki Hyeong Lee, Dae Seog Heo, Yung Jue Bang, Kwang Hyun Kim, Charn II Park, Noe Kyeong Kim; J Korean Cancer Assoc. 1996;28(1):94-104.

Abstract PDF: Twenty-nine patients with previously untreated, locally advanced head and neck cancer were treated with two or three cycles of combination chemotherapy consisting of 5- fluorouracil infusion and carboplatin, followed by surgery and/or curative radiotherapy. Nine patients with recurrent head and neck cancer were treated with the same combination chemotherapy. The results were as follows; 1) Among 28 evaluable patients, response rate was 71.4%(partial response) after neoadjuvant chemotherapy. Following local modality(surgery and/or radiotherapy), response rate was 79%(complete response 51.4%, and partial response 25%). 2) One year survival rate in neoadjuvant group was 83% and one year progression-free survival rate, 68.8%. The progression-free survival of responders was significantly prolonged in comparison with that of non-responders(p<0.05). 3) In palliative treatment group, one partial response(11%) was observed among nine patients. Median time to progression was 6.8 weeks and median survival was 17.7 weeks; there was no significant difference between responders and non-responders. 4) Nausea and vomiting were frequently observed but easily controlled. Hematologic toxicities-leukopenia and thrombocytopenia were observed but were reversible. In conclusion, combination chemotherapy with carboplatin and 5-FU was effective for locally advanced head and neck cancer in neoadjuvant setting, but it had limited benefits for recurrent diseases. Toxicities were tolerable and neurotoxicity, ototoxicity, and nephrotoxicity were not observed.

3,454 View
25 Download

First
Prev
Page of 1
Next
Last

Search